1
|
Legrand M, Pissaloux D, Tirode F, Tallet A, Collin C, Chantreau PL, Berthon P, Jullie ML, Sohier P, Calonje E, Luzar B, Moulonguet I, Goto K, Cokelaere K, Lamant L, Balme B, Deschamps L, Macagno N, Cribier B, Battistella M, de la Fouchardière A, Kervarrec T. SSTR2A is a diagnostic marker of trichogerminoma. J Eur Acad Dermatol Venereol 2023; 37:e1344-e1347. [PMID: 37421254 DOI: 10.1111/jdv.19319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2023] [Accepted: 06/27/2023] [Indexed: 07/10/2023]
Affiliation(s)
- Mélanie Legrand
- Department of Pathology, Université de Tours, Centre Hospitalier Universitaire de Tours, Tours, France
| | - Daniel Pissaloux
- Department of Biopathology, Center Léon Bérard, Lyon, France
- Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer, Lyon, France
| | - Franck Tirode
- Department of Biopathology, Center Léon Bérard, Lyon, France
- Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer, Lyon, France
| | - Anne Tallet
- Platform of Somatic Tumor Molecular Genetics, Université de Tours, Centre Hospitalier Universitaire de Tours, Tours, France
| | - Christine Collin
- Platform of Somatic Tumor Molecular Genetics, Université de Tours, Centre Hospitalier Universitaire de Tours, Tours, France
| | - Paul-Louis Chantreau
- Department of Pathology, Université de Tours, Centre Hospitalier Universitaire de Tours, Tours, France
| | - Patricia Berthon
- "Biologie des infections à polyomavirus" team, UMR INRA ISP 1282, Université de Tours, Tours, France
| | - Marie-Laure Jullie
- French Network of Rare Skin Cancers, CARADERM, France
- Department of Pathology, Hôpital Haut-Lévêque, CHU de Bordeaux, Pessac, France, CARADERM network
| | - Pierre Sohier
- French Network of Rare Skin Cancers, CARADERM, France
- Department of Pathology, Hôpital Cochin, AP-HP, AP-HP.Centre - Faculté de Médecine, University Paris Cité, Paris, France
| | - Eduardo Calonje
- Department of Dermatopathology, St John's Institute of Dermatology, St Thomas's Hospital, London, UK
| | - Boštjan Luzar
- Institute of Pathology, Medical Faculty University of Ljubljana, Ljubljana, Slovenia
| | - Isabelle Moulonguet
- Department of Pathology, APHP Hôpital Saint Louis, Université Paris Cité, Paris, France
| | - Keisuke Goto
- Department of Pathology, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Tokyo, Japan
- Department of Diagnostic Pathology, Shizuoka Cancer Center Hospital, Japan
- Department of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka, Japan
- Department of Dermatology, Hyogo Cancer Center, Akashi, Japan
| | | | - Laurence Lamant
- Department of Pathology, CHU Toulouse, Institut Universitaire du Cancer Toulouse Oncopole, Université Toulouse III Paul Sabatier, Toulouse, France
| | - Brigitte Balme
- Department of Pathology, Centre Hospitalier Universitaire de Lyon, Lyon, France
| | - Lydia Deschamps
- Department of Pathology, APHP Bichat Hospital, Paris, France
| | - Nicolas Macagno
- French Network of Rare Skin Cancers, CARADERM, France
- Department of Pathology, Timone University Hospital, Marseille, France
| | - Bernard Cribier
- French Network of Rare Skin Cancers, CARADERM, France
- Dermatology Clinic, Hôpitaux Universitaires & Université de Strasbourg, Hôpital Civil, Strasbourg, France
| | - Maxime Battistella
- French Network of Rare Skin Cancers, CARADERM, France
- Department of Pathology, APHP Hôpital Saint Louis, Université Paris Cité, Paris, France
| | - Arnaud de la Fouchardière
- Department of Biopathology, Center Léon Bérard, Lyon, France
- Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer, Lyon, France
| | - Thibault Kervarrec
- Department of Pathology, Université de Tours, Centre Hospitalier Universitaire de Tours, Tours, France
- "Biologie des infections à polyomavirus" team, UMR INRA ISP 1282, Université de Tours, Tours, France
- French Network of Rare Skin Cancers, CARADERM, France
| |
Collapse
|
2
|
Kervarrec T, Tallet A, Macagno N, de la Fouchardière A, Pissaloux D, Tirode F, Bravo IG, Nicolas A, Baulande S, Sohier P, Balme B, Osio A, Jullie ML, Moulonguet I, Bonsang B, Tournier E, Herfs M, Frouin E, Zidan A, Calonje E, Berthon P, Touzé A, Seris A, Mortier L, Jouary T, Cribier B, Battistella M. Sweat Gland Tumors Arising on Acral Sites: A Molecular Survey. Am J Surg Pathol 2023; 47:1096-1107. [PMID: 37505808 DOI: 10.1097/pas.0000000000002098] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/29/2023]
Abstract
Recurrent oncogenic drivers have been identified in a variety of sweat gland tumors. Recently, integration of human papillomavirus type 42 (HPV42) has been reported in digital papillary adenocarcinoma (DPA). The main objectives of the present study were (i) to provide an overview of the prevalence of previously identified oncogenic drivers in acral sweat gland tumors and (ii) to genetically characterize tumors in which no recurrent genetic alteration has been identified yet. Cases of acral sweat gland tumors were identified from the database of the French network CARADERM. After histologic review, the presence of previously identified genetic alterations was investigated in the entire cohort (n=79) using a combination of immunohistochemistry and targeted DNA and RNA sequencing. Tumor entities with no recurrent genetic alterations were submitted to whole-transcriptome sequencing. CRTC1::MAML2 fusion was identified in cases of hidradenoma and hidradenocarcinoma (n=9/12 and n=9/12). A p.V600E mutation of BRAF was observed in all cases of tubular adenoma (n=4). YAP1:MAML2 and YAP1::NUTM1 fusions were observed in poroid tumors (n=15/25). ETV6::NTRK3 and TRPS1::PLAG1 fusion transcripts were identified in secretory carcinoma (n=1/1) and cutaneous mixed tumors (n=3/4), respectively. The HPV42 genome was detected in most cases of DPA (n=10/11) and in 1 adnexal adenocarcinoma not otherwise specified. Finally, whole-transcriptome analysis revealed BRD3::NUTM1 or NSD3::NUTM1 fusions in 2 cases of NUT adnexal carcinoma and NCOA4::RET and CCDC6::RET fusion transcripts in 2 cystadenoma/hidrocystoma-like tumors. Our study confirms distinctive cytogenetic abnormalities in a wide number of acral adnexal neoplasms and supports the use of molecular analysis as a valuable aid in the diagnosis of these rare and often difficult to diagnose group of neoplasms.
Collapse
Affiliation(s)
- Thibault Kervarrec
- CARADERM, French Network of Rare Cutaneous Cancer
- Department of Pathology, University Hospital Center of Tours
- "Biologie des infections polyomavirus" Team, UMR INRA ISP1282, University of Tours
| | - Anne Tallet
- Platform of Solid Tumor Molecular Genetics, University Hospital Center of Tours, Tours
| | - Nicolas Macagno
- CARADERM, French Network of Rare Cutaneous Cancer
- Department of Pathology, APHM, Timone University Hospital
- Aix Marseille University, INSERM, MMG, UMR1251, Marmara Institute, Marseille
| | - Arnaud de la Fouchardière
- CARADERM, French Network of Rare Cutaneous Cancer
- Department of Biopathology, Center Léon Bérard
- University of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer
| | - Daniel Pissaloux
- Department of Biopathology, Center Léon Bérard
- University of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer
| | - Franck Tirode
- University of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer
| | - Ignacio G Bravo
- French National Center for Scientific Research (CNRS), Laboratory MIVEGEC (CNRS IRD Univ Montpellier), Montpellier
| | - Alain Nicolas
- Institut Curie, PSL Research University, CNRS UMR3244
| | | | - Pierre Sohier
- CARADERM, French Network of Rare Cutaneous Cancer
- Faculté de Médecine Paris Centre Santé, University of Paris
- Department of Pathology, Cochin Hospital, AP-HP, AP-HP Centre-Université de Paris
| | - Brigitte Balme
- CARADERM, French Network of Rare Cutaneous Cancer
- Department of Pathology, University Hospital Center of Lyon-Sud, Hospices Civils de Lyon, Lyon
| | - Amélie Osio
- CARADERM, French Network of Rare Cutaneous Cancer
- National Center of Dermatopathology, Paris-la Roquette, Ivry
| | - Marie-Laure Jullie
- CARADERM, French Network of Rare Cutaneous Cancer
- Department of Pathology, University Hospital Center of Bordeaux, Pessac
| | | | - Benjamin Bonsang
- CARADERM, French Network of Rare Cutaneous Cancer
- Department of Pathology, Hôpital Ambroise Pare, AP-HP
| | - Emilie Tournier
- CARADERM, French Network of Rare Cutaneous Cancer
- Department of Pathology, CHU Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole
- Université Toulouse III Paul Sabatier, Toulouse
| | - Michael Herfs
- Laboratory of Experimental Pathology, GIGA-Cancer, University of Liège, Liège, Belgium
| | - Eric Frouin
- Department of Pathology, University Hospital Center of Poitiers, LITEC, UR 15560, University of Poitiers, Poitiers
| | - Anoud Zidan
- Dermatopathology Laboratory, St John's Institute of Dermatology, St Thomas' Hospital, London, UK
| | - Eduardo Calonje
- Dermatopathology Laboratory, St John's Institute of Dermatology, St Thomas' Hospital, London, UK
| | - Patricia Berthon
- "Biologie des infections polyomavirus" Team, UMR INRA ISP1282, University of Tours
| | - Antoine Touzé
- "Biologie des infections polyomavirus" Team, UMR INRA ISP1282, University of Tours
| | - Alice Seris
- CARADERM, French Network of Rare Cutaneous Cancer
- Department of Dermatology, Hospital Center of Pau, Pau
| | - Laurent Mortier
- CARADERM, French Network of Rare Cutaneous Cancer
- Department of Dermatology, University Hospital Center of Lille, Lille
| | - Thomas Jouary
- CARADERM, French Network of Rare Cutaneous Cancer
- Department of Dermatology, Hospital Center of Pau, Pau
| | - Bernard Cribier
- CARADERM, French Network of Rare Cutaneous Cancer
- Clinique Dermatologique, Hôpitaux Universitaires & Université de Strasbourg, Hôpital Civil, Strasbourg, France
| | - Maxime Battistella
- CARADERM, French Network of Rare Cutaneous Cancer
- Department of Pathology, Hopital Saint Louis, AP-HP Universite ́ Paris 7, Paris
| |
Collapse
|
3
|
Ribereau-Gayon E, Donzel M, Pham F, Romain-Scelle N, Perier-Muzet M, Balme B, Traverse-Glehen A, Ghesquières H, Dalle S. Brentuximab-vedotin in combination with cyclophosphamide, doxorubicin, prednisolone for the treatment of aggressive CD30-positive cutaneous T-cell lymphomas. Leuk Lymphoma 2023; 64:1424-1432. [PMID: 37255021 DOI: 10.1080/10428194.2023.2216820] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2022] [Revised: 04/26/2023] [Accepted: 05/16/2023] [Indexed: 06/01/2023]
Abstract
Aggressive CD30-positive cutaneous T-cell lymphomas (CD30+CTCL) are associated with unfavorable prognosis. Anthracycline-based polychemotherapy (CHOP) and brentuximab-vedotin (BV) monotherapy are related to poor outcomes in case of extracutaneous involvement or rapidly-progressing disease. Our objective was to assess the effectiveness of BV + CHP in aggressive CD30+CTCL. We included 7 patients treated with BV + CHP from April 2015 to January 2022: 4 had mycosis fungoides with large-cell transformation, 2 had primary cutaneous anaplastic large-cell lymphoma, and 1 harbored a primary cutaneous aggressive epidermotropic CD8-positive T-cell lymphoma. After a median [IQR] follow-up of 17.2 [13.2-21.0] months, 6/7 patients achieved an ORR lasting ≥4 months. The median [IQR] duration of response was 9.5 [5.9-11.1] months and the median [IQR] progression free survival was 14.9 [11.6-16.4] months. Four patients displayed progression with a median (range) time to next treatment of 15.8 (6.5-16.3) months. Two grade-3 adverse events were reported: febrile neutropenia and thromboembolic event. BV + CHP displayed substantial antitumor activity and favorable safety profile in 7 patients with aggressive CD30+CTCL.
Collapse
Affiliation(s)
- Emmanuel Ribereau-Gayon
- Service de Dermatologie, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre Bénite, France
- Université Claude Bernard Lyon 1, Lyon, France
| | - Marie Donzel
- Hospices Civils de Lyon, Hôpital Lyon Sud, Service de Pathologie, Pierre Bénite, France
| | - Felix Pham
- Service de Dermatologie, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre Bénite, France
| | - Nicolas Romain-Scelle
- Hospices Civils de Lyon, Hôpital Lyon Sud, Service de Santé Publique, Pierre Bénite, France
| | - Marie Perier-Muzet
- Service de Dermatologie, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre Bénite, France
| | - Brigitte Balme
- Hospices Civils de Lyon, Hôpital Lyon Sud, Service de Pathologie, Pierre Bénite, France
| | | | - Hervé Ghesquières
- Hospices Civils de Lyon, Hôpital Lyon Sud, Service d'Hématologie, Pierre Bénite, France
| | - Stéphane Dalle
- Service de Dermatologie, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre Bénite, France
| |
Collapse
|
4
|
Donzel M, Trecourt A, Balme B, Harou O, Mauduit C, Bachy E, Guesquières H, Fontaine J, Ortonne N, Perier-Muzet M, Dalle S, Traverse-Glehen A. Deciphering the spectrum of cutaneous lymphomas expressing TFH markers. Sci Rep 2023; 13:6500. [PMID: 37081015 PMCID: PMC10119163 DOI: 10.1038/s41598-023-33031-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2022] [Accepted: 04/06/2023] [Indexed: 04/22/2023] Open
Abstract
T-follicular helper (TFH) markers are expressed in the microenvironnement of marginal zone B-cell lymphoma (MZL), and in lymphomas arising from TFH-cells, sometimes making the differential diagnosis difficult. In the skin, the "TFH-spectrum" is poorly defined, going from primary cutaneous lymphoproliferative disorder with small/medium CD4+ T-cells (SMLPD) to cutaneous localizations of systemic angioimmunoblastic T-cell lymphoma (cAITL), and may pass through intermediate forms (primary cutaneous T-follicular helper derived lymphoma, not otherwise specified (PCTFHL,NOS)). We retrospectively analyzed 20 MZL, 13 SMLPD, 5 PCTFHL, and 11 cAITL clinically, histologically, and molecularly, to define tools to differentiate them. Characteristics that might favor the diagnosis of MZL over SMLPD are: multiple skin nodules (p < 0.001), nodular architecture (p < 0.01), residual germinal centers with follicular dendritic cell network (p < 0.001), monotypic plasma cells (p < 0.001), and few staining with PD1 (p = 0.016) or CXCL13 (p = 0.03). PCTFHL and cAITL presented as multiple (p < 0.01) lesions, in older patients (p < 0.01), with systemic symptoms and/or biological alterations (p < 0.01). Immunophenotypic loss of T-cell markers (p < 0.001), BCL6 (p = 0.023) and/or CD10 staining (p = 0.08), and a higher proliferative index (≥ 30%, p = 0.039) favoured these diagnoses over SMLPD. Pathogenic variants were observed by genomic sequencing in 47% of MZL (TNFAIP3 (32%), EP300 (21%), NOTCH2 (16%), KMT2D (16%), CARD11 (10.5%)), 8% of SMLPD (TET2), 40% of PCTFHL (SOCS1 (20%), ARID1A (20%)) and 64% of cAITL (TET2 (63.6%), RHOA (36.4%), NOTCH1 (9%)). This study characterizes the various clinical and histological features between cutaneous lymphomas expressing TFH markers and highlights the value of the interest of screening for genomic mutations in difficult cases.
Collapse
Affiliation(s)
- Marie Donzel
- Institut de Pathologie multisites, Hospices Civils de Lyon, Hôpital Lyon Sud, 165 Chemin du Grand Revoyet, 69310, Lyon, Pierre-Bénite, France.
| | - Alexis Trecourt
- Institut de Pathologie multisites, Hospices Civils de Lyon, Hôpital Lyon Sud, 165 Chemin du Grand Revoyet, 69310, Lyon, Pierre-Bénite, France
| | - Brigitte Balme
- Institut de Pathologie multisites, Hospices Civils de Lyon, Hôpital Lyon Sud, 165 Chemin du Grand Revoyet, 69310, Lyon, Pierre-Bénite, France
| | - Olivier Harou
- Institut de Pathologie multisites, Hospices Civils de Lyon, Hôpital Lyon Sud, 165 Chemin du Grand Revoyet, 69310, Lyon, Pierre-Bénite, France
| | - Claire Mauduit
- Institut de Pathologie multisites, Hospices Civils de Lyon, Hôpital Lyon Sud, 165 Chemin du Grand Revoyet, 69310, Lyon, Pierre-Bénite, France
| | - Emmanuel Bachy
- Hospices Civils de Lyon, Cancer Research Center of Lyon, INSERM U1052, CNRS UMR 5286, CLB, UCBL, Université Lyon 1, Lyon, France
- Hospices Civils de Lyon, Service d'Hématologie, Hôpital Lyon Sud, Lyon, France
| | - Hervé Guesquières
- Hospices Civils de Lyon, Cancer Research Center of Lyon, INSERM U1052, CNRS UMR 5286, CLB, UCBL, Université Lyon 1, Lyon, France
- Hospices Civils de Lyon, Service d'Hématologie, Hôpital Lyon Sud, Lyon, France
| | - Juliette Fontaine
- Institut de Pathologie multisites, Hospices Civils de Lyon, Hôpital Lyon Sud, 165 Chemin du Grand Revoyet, 69310, Lyon, Pierre-Bénite, France
| | - Nicolas Ortonne
- Biological Immunology, APHP Henri Mondor Hospital, Paris Est Creteil University (UPEC) and INSERM U955 Team Ortonne (NFL), Créteil, France
- Department of Dermatology, APHP Henri Mondor Hospital, Créteil, France
| | - Marie Perier-Muzet
- Hospices Civils de Lyon, Service de Dermatologie, Hôpital Lyon Sud, Lyon, France
| | - Stéphane Dalle
- Hospices Civils de Lyon, Cancer Research Center of Lyon, INSERM U1052, CNRS UMR 5286, CLB, UCBL, Université Lyon 1, Lyon, France
- Hospices Civils de Lyon, Service de Dermatologie, Hôpital Lyon Sud, Lyon, France
| | - Alexandra Traverse-Glehen
- Institut de Pathologie multisites, Hospices Civils de Lyon, Hôpital Lyon Sud, 165 Chemin du Grand Revoyet, 69310, Lyon, Pierre-Bénite, France
- Hospices Civils de Lyon, Cancer Research Center of Lyon, INSERM U1052, CNRS UMR 5286, CLB, UCBL, Université Lyon 1, Lyon, France
| |
Collapse
|
5
|
Antherieu G, Donzel M, Balme B, Traverse-Glehen A, Heiblig M. Chronic myelomonocytic leukemia transdifferentiation landscape: From histiocytosis to blastic plasmacytoid dendritic cell neoplasm. Am J Hematol 2023. [PMID: 36785518 DOI: 10.1002/ajh.26876] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2022] [Revised: 01/27/2023] [Accepted: 02/01/2023] [Indexed: 02/15/2023]
Affiliation(s)
- Gabriel Antherieu
- Hematology Department, Hopital Lyon Sud, Hospices Civils de Lyon, Lyon, France
| | - Marie Donzel
- Pathology Department, Hopital Lyon Sud, Hospices Civils de Lyon, Lyon, France
| | - Brigitte Balme
- Pathology Department, Hopital Lyon Sud, Hospices Civils de Lyon, Lyon, France
| | | | - Maël Heiblig
- Hematology Department, Hopital Lyon Sud, Hospices Civils de Lyon, Lyon, France
| |
Collapse
|
6
|
Kervarrec T, Frouin E, Collin C, Tallet A, Tallegas M, Pissaloux D, Tirode F, Guyétant S, Samimi M, Gaboriaud P, Touzé A, Schrama D, Houben R, Tabareau-Delalande F, Neuhart A, de la Fouchardière A, Osio A, Cavelier-Balloy B, Laurent-Roussel S, Sohier P, Cyprien T, Balme B, Belzung F, Jullie ML, Cribier B, Battistella M, Macagno N. Distinct regulations driving YAP1 expression loss in poroma, porocarcinoma and RB1-deficient skin carcinoma. Histopathology 2023; 82:885-898. [PMID: 36720791 DOI: 10.1111/his.14874] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2022] [Revised: 12/22/2022] [Accepted: 01/15/2023] [Indexed: 02/02/2023]
Abstract
AIMS Recently, YAP1 fusion genes have been demonstrated in eccrine poroma and porocarcinoma, and the diagnostic use of YAP1 immunohistochemistry has been highlighted in this setting. In other organs, loss of YAP1 expression can reflect YAP1 rearrangement or transcriptional repression, notably through RB1 inactivation. In this context, our objective was to re-evaluate the performance of YAP1 immunohistochemistry for the diagnosis of poroma and porocarcinoma. METHODS AND RESULTS The expression of the C-terminal part of the YAP1 protein was evaluated by immunohistochemistry in 543 cutaneous epithelial tumours, including 27 poromas, 14 porocarcinomas and 502 other cutaneous tumours. Tumours that showed a lack of expression of YAP1 were further investigated for Rb by immunohistochemistry and for fusion transcripts by real-time PCR (YAP1::MAML2 and YAP1::NUTM1). The absence of YAP1 expression was observed in 24 cases of poroma (89%), 10 porocarcinoma (72%), 162 Merkel cell carcinoma (98%), 14 squamous cell carcinoma (SCC) (15%), one trichoblastoma and one sebaceoma. Fusions of YAP1 were detected in only 16 cases of poroma (n = 66%), 10 porocarcinoma (71%) all lacking YAP1 expression, and in one sebaceoma. The loss of Rb expression was detected in all cases except one of YAP1-deficient SCC (n = 14), such tumours showing significant morphological overlap with porocarcinoma. In-vitro experiments in HaCat cells showed that RB1 knockdown resulted in repression of YAP1 protein expression. CONCLUSION In addition to gene fusion, we report that transcriptional repression of YAP1 can be observed in skin tumours with RB1 inactivation, including MCC and a subset of SCC.
Collapse
Affiliation(s)
- Thibault Kervarrec
- CARADERM, French Network of Rare Cutaneous Cancer, Lille, France.,Department of Pathology, University Hospital of Tours, Tours, France.,'Biologie des Infections à Polyomavirus' Team, UMR1282 INRAE, University of Tours, Tours, France
| | - Eric Frouin
- CARADERM, French Network of Rare Cutaneous Cancer, Lille, France.,Department of Pathology, University Hospital of Poitiers, University of Poitiers, LITEC, Poitiers, France
| | - Christine Collin
- Platform of Solid Tumor Molecular Genetics, University Hospital Center of Tours, Tours, France
| | - Anne Tallet
- Platform of Solid Tumor Molecular Genetics, University Hospital Center of Tours, Tours, France
| | - Matthias Tallegas
- Platform of Solid Tumor Molecular Genetics, University Hospital Center of Tours, Tours, France
| | - Daniel Pissaloux
- Department of Biopathology, Center Léon Bérard, Lyon, France.,University of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer, Lyon, France
| | - Franck Tirode
- Department of Biopathology, Center Léon Bérard, Lyon, France.,University of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer, Lyon, France
| | - Serge Guyétant
- Department of Pathology, University Hospital of Tours, Tours, France.,'Biologie des Infections à Polyomavirus' Team, UMR1282 INRAE, University of Tours, Tours, France.,Department of Pathology, University Hospital of Poitiers, University of Poitiers, LITEC, Poitiers, France
| | - Mahtab Samimi
- Department of Dermatology, University Hospital Center of Tours, Tours, France
| | - Pauline Gaboriaud
- 'Biologie des Infections à Polyomavirus' Team, UMR1282 INRAE, University of Tours, Tours, France
| | - Antoine Touzé
- 'Biologie des Infections à Polyomavirus' Team, UMR1282 INRAE, University of Tours, Tours, France
| | - David Schrama
- Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany
| | - Roland Houben
- Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany
| | | | - Anne Neuhart
- Department of Biopathology, Center Léon Bérard, Lyon, France
| | - Arnaud de la Fouchardière
- CARADERM, French Network of Rare Cutaneous Cancer, Lille, France.,Department of Biopathology, Center Léon Bérard, Lyon, France.,University of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer, Lyon, France
| | - Amélie Osio
- CARADERM, French Network of Rare Cutaneous Cancer, Lille, France.,Department of Pathology, Hospital Saint-Louis, AP-HP, Université Paris Cité, INSERM U976, Paris, France.,Centre National de Dermatopathologie, Paris-la Roquette, Ivry, France
| | | | - Sara Laurent-Roussel
- Centre National de Dermatopathologie, Paris-la Roquette, Ivry, France.,Cabinet Mathurin Moreau, Paris, France
| | - Pierre Sohier
- CARADERM, French Network of Rare Cutaneous Cancer, Lille, France.,Department of Pathology, Hôpital Cochin, AP-HP, AP-HP.Centre - Université Paris Cité, Paris, France.,Faculté de Médecine, University Paris Cité, Paris, France
| | - Tilmant Cyprien
- CARADERM, French Network of Rare Cutaneous Cancer, Lille, France.,Department of Pathology, Groupement des Hopitaux de l'institut catholique de Lille, Lille, France
| | - Brigitte Balme
- CARADERM, French Network of Rare Cutaneous Cancer, Lille, France.,Department of Pathology, University Hospital of Lyon Sud, Lyon, France
| | - Fanny Belzung
- Department of Pathology, University Hospital of Bordeaux, Bordeaux, France
| | - Marie-Laure Jullie
- CARADERM, French Network of Rare Cutaneous Cancer, Lille, France.,Department of Pathology, University Hospital of Bordeaux, Bordeaux, France
| | - Bernard Cribier
- CARADERM, French Network of Rare Cutaneous Cancer, Lille, France.,Clinique Dermatologique, Hôpitaux Universitaires and Université de Strasbourg, Hôpital Civil, Strasbourg, France
| | - Maxime Battistella
- CARADERM, French Network of Rare Cutaneous Cancer, Lille, France.,Department of Pathology, Hospital Saint-Louis, AP-HP, Université Paris Cité, INSERM U976, Paris, France
| | - Nicolas Macagno
- CARADERM, French Network of Rare Cutaneous Cancer, Lille, France.,Department of Pathology, APHM, Timone University Hospital, Marseille, France.,Aix-Marseille University, INSERM U1251, MMG, Marseille, France
| |
Collapse
|
7
|
Donzel M, Bon Mardion M, Balme B. [A particular presentation of a T cell large granular lymphocytic leukaemia]. Ann Pathol 2023; 43:52-56. [PMID: 36494259 DOI: 10.1016/j.annpat.2022.09.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2022] [Revised: 05/16/2022] [Accepted: 09/21/2022] [Indexed: 12/12/2022]
Abstract
T cell prolymphocytic leukemia (T-PLL) is a rare, aggressive neoplasm derived from post-thymic T cells. Patients are typically middle-aged with a slight male predominance who present with a high white blood cell count, hepatosplenomegaly, lymphadenopathy, and other symptoms typically associated with leukemia. Although cutaneous involvement has been reported in up to 30% of cases of T-PLL, to our knowledge, none have presented with a presentation resembling livedoid vasculopathy. In the correct clinical context, an underlying hematolymphoid neoplasm should be included in the differential diagnosis of a patient presenting with livedoid vasculopathy.
Collapse
Affiliation(s)
- Marie Donzel
- Hospices civils de Lyon, Institut de pathologie multisite, centre hospitalier universitaire Lyon Sud, Pierre-Bénite, France.
| | - Mathilde Bon Mardion
- Département de dermatologie, centre hospitalier Nord-Ouest de Villefranche-sur-Saône, Villefranche-sur-Saône, France
| | - Brigitte Balme
- Hospices civils de Lyon, Institut de pathologie multisite, centre hospitalier universitaire Lyon Sud, Pierre-Bénite, France
| |
Collapse
|
8
|
Wang L, Rocas D, Dalle S, Sako N, Pelletier L, Martin N, Dupuy A, Tazi N, Balme B, Vergier B, Beylot-Barry M, Carlotti A, Bagot M, Battistella M, Chaby G, Ingen-Housz-Oro S, Gaulard P, Ortonne N. Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study. Br J Dermatol 2022; 187:970-980. [PMID: 35895386 PMCID: PMC10087773 DOI: 10.1111/bjd.21791] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2022] [Revised: 07/04/2022] [Accepted: 07/22/2022] [Indexed: 12/24/2022]
Abstract
BACKGROUND Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype (pcTFH-PTCL) are poorly characterized, and often compared to, but not corresponding with, mycosis fungoides (MF), Sézary syndrome, primary cutaneous CD4+ lymphoproliferative disorder, and skin manifestations of angioimmunoblastic T-cell lymphomas (AITL). OBJECTIVES We describe the clinicopathological features of pcTFH-PTCL in this original series of 23 patients, and also characterize these cases molecularly. METHODS Clinical and histopathological data of the selected patients were reviewed. Patient biopsy samples were also analysed by targeted next-generation sequencing. RESULTS All patients (15 men, eight women; median age 66 years) presented with skin lesions, without systemic disease. Most were stage T3b, with nodular (n = 16), papular (n = 6) or plaque (atypical for MF, n = 1) lesions. Three (13%) developed systemic disease and died of lymphoma. Nine (39%) patients received more than one line of chemotherapy. Histologically, the lymphomas were CD4+ T-cell proliferations, usually dense and located in the deep dermis (n = 14, 61%), with the expression of at least two TFH markers (CD10, CXCL13, PD1, ICOS, BCL6), including three markers in 16 cases (70%). They were associated with a variable proportion of B cells. Eight patients were diagnosed with an associated B-cell lymphoproliferative disorder (LPD) on biopsy, including Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (n = 3), EBV+ LPD (n = 1) and monotypic plasma cell LPD (n = 4). Targeted sequencing showed four patients to have a mutated TET2-RHOAG17V association (as frequently seen in AITL) and another a TET2/DNMT3A/PLCG1/SETD2 mutational profile. The latter patient, one with a TET2-RHOA association, and one with no detected mutations, developed systemic disease and died. Five other patients showed isolated mutations in TET2 (n = 1), PLCG1 (n = 2), SETD2 (n = 1) or STAT5B (n = 1). CONCLUSIONS Patients with pcTFH-PTCL have pathological and genetic features that overlap with those of systemic lymphoma of TFH derivation. Clinically, most remained confined to the skin, with only three patients showing systemic spread and death. Whether pcTFH-PTCL should be integrated as a new subgroup of TFH lymphomas in future classifications is still a matter of debate. What is already known about this topic? There is a group of cutaneous lymphomas that express T-follicular helper (TFH) markers that do not appear to correspond to existing World Health Organization diagnostic entities. These include mycosis fungoides, Sézary syndrome, or primary cutaneous CD4+ small/medium-sized T-cell lymphoproliferative disorder or cutaneous extensions of systemic peripheral T-cell lymphomas (PTCL) with TFH phenotype. What does this study add? This is the first large original series of patients with a diagnosis of primary cutaneous PTCL with a TFH phenotype (pcTFH-PTCL) to be molecularly characterized. pcTFH-PTCL may be a standalone group of cutaneous lymphomas with clinicopathological and molecular characteristics that overlap with those of systemic TFH lymphomas, such as angioimmunoblastic T-cell lymphoma, and does not belong to known diagnostic groups of cutaneous lymphoma. This has an impact on the treatment and follow-up of patients; the clinical behaviour needs to be better clarified in further studies to tailor patient management.
Collapse
Affiliation(s)
- Luojun Wang
- Department of Pathology, Assistance Publique - Hôpitaux de Paris, Henri-Mondor Hospital, 94010, Créteil, France.,INSERM U955 Institut Mondor de Recherche Biomédicale (IMRB), Paris Est Créteil University, 94010, Créteil, France
| | - Delphine Rocas
- Department of Pathology, Lyon Sud, Pierre-Bénite Hospital, 69495, Lyon, France
| | - Stéphane Dalle
- Department of Dermatology, Lyon Sud, Pierre-Bénite Hospital, 69495, Lyon, France
| | - Nouhoum Sako
- INSERM U955 Institut Mondor de Recherche Biomédicale (IMRB), Paris Est Créteil University, 94010, Créteil, France
| | - Laura Pelletier
- INSERM U955 Institut Mondor de Recherche Biomédicale (IMRB), Paris Est Créteil University, 94010, Créteil, France
| | - Nadine Martin
- INSERM U955 Institut Mondor de Recherche Biomédicale (IMRB), Paris Est Créteil University, 94010, Créteil, France
| | - Aurélie Dupuy
- INSERM U955 Institut Mondor de Recherche Biomédicale (IMRB), Paris Est Créteil University, 94010, Créteil, France
| | - Nadia Tazi
- Department of Pathology, Assistance Publique - Hôpitaux de Paris, Henri-Mondor Hospital, 94010, Créteil, France
| | - Brigitte Balme
- Department of Pathology, Lyon Sud, Pierre-Bénite Hospital, 69495, Lyon, France
| | - Béatrice Vergier
- Department of Pathology, CHU de Bordeaux, Haut-Lévêque Hospital, 33600, Pessac, France.,INSERM, U1312, Université de Bordeaux, 33000, Bordeaux, France
| | - Marie Beylot-Barry
- INSERM, U1312, Université de Bordeaux, 33000, Bordeaux, France.,Department of Dermatology, CHU de Bordeaux, Saint-André Hospital, 33000, Bordeaux, France
| | - Agnès Carlotti
- Department of Pathology, Assistance Publique - Hôpitaux de Paris, Cochin Hospital, 75014, Paris, France
| | - Martine Bagot
- Department of Dermatology, Assistance Publique - Hôpitaux de Paris, Saint-Louis Hospital, 75010, Université Paris Cité, Paris, France
| | - Maxime Battistella
- Department of Pathology, Assistance Publique - Hôpitaux de Paris, Saint-Louis Hospital, 75010, Université Paris Cité, Paris, France
| | - Guillaume Chaby
- Department of Dermatology, CHU d'Amiens-Picardie, Hôpital Sud, 80054, Amiens, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, Assistance Publique - Hôpitaux de Paris, Henri-Mondor Hospital, 94010, Créteil, France
| | - Philippe Gaulard
- Department of Pathology, Assistance Publique - Hôpitaux de Paris, Henri-Mondor Hospital, 94010, Créteil, France.,INSERM U955 Institut Mondor de Recherche Biomédicale (IMRB), Paris Est Créteil University, 94010, Créteil, France
| | - Nicolas Ortonne
- Department of Pathology, Assistance Publique - Hôpitaux de Paris, Henri-Mondor Hospital, 94010, Créteil, France.,INSERM U955 Institut Mondor de Recherche Biomédicale (IMRB), Paris Est Créteil University, 94010, Créteil, France
| |
Collapse
|
9
|
Marques AC, Ferraro-Peyret C, Michaud F, Song L, Smith E, Fabre G, Willig A, Wong MML, Xing X, Chong C, Brayer M, Fenouil T, Hervieu V, Bancel B, Devouassoux M, Balme B, Meyronet D, Menu P, Lopez J, Xu Z. Improved NGS-based detection of microsatellite instability using tumor-only data. Front Oncol 2022; 12:969238. [PMID: 36465367 PMCID: PMC9714634 DOI: 10.3389/fonc.2022.969238] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2022] [Accepted: 10/18/2022] [Indexed: 01/09/2024] Open
Abstract
Microsatellite instability (MSI) is a molecular signature of mismatch repair deficiency (dMMR), a predictive marker of immune checkpoint inhibitor therapy response. Despite its recognized pan-cancer value, most methods only support detection of this signature in colorectal cancer. In addition to the tissue-specific differences that impact the sensitivity of MSI detection in other tissues, the performance of most methods is also affected by patient ethnicity, tumor content, and other sample-specific properties. These limitations are particularly important when only tumor samples are available and restrict the performance and adoption of MSI testing. Here we introduce MSIdetect, a novel solution for NGS-based MSI detection. MSIdetect models the impact of indel burden and tumor content on read coverage at a set of homopolymer regions that we found are minimally impacted by sample-specific factors. We validated MSIdetect in 139 Formalin-Fixed Paraffin-Embedded (FFPE) clinical samples from colorectal and endometrial cancer as well as other more challenging tumor types, such as glioma or sebaceous adenoma or carcinoma. Based on analysis of these samples, MSIdetect displays 100% specificity and 96.3% sensitivity. Limit of detection analysis supports that MSIdetect is sensitive even in samples with relatively low tumor content and limited microsatellite instability. Finally, the results obtained using MSIdetect in tumor-only data correlate well (R=0.988) with what is obtained using tumor-normal matched pairs, demonstrating that the solution addresses the challenges posed by MSI detection from tumor-only data. The accuracy of MSI detection by MSIdetect in different cancer types coupled with the flexibility afforded by NGS-based testing will support the adoption of MSI testing in the clinical setting and increase the number of patients identified that are likely to benefit from immune checkpoint inhibitor therapy.
Collapse
Affiliation(s)
| | - Carole Ferraro-Peyret
- Cancer Research Centre of Lyon, INSERM 1052, Centre National de la Recherche Scientifique (CNRS) 5286, University of Lyon, Lyon, France
- Hospices Civils de Lyon, Biopathology of Tumours, GH Est (GHE) Hospital, Bron, France
| | | | - Lin Song
- SOPHiA GENETICS, Saint-Sulpice, Switzerland
| | - Ewan Smith
- SOPHiA GENETICS, Saint-Sulpice, Switzerland
| | | | | | | | | | | | | | - Tanguy Fenouil
- Hospices Civils de Lyon, Biopathology of Tumours, GH Est (GHE) Hospital, Bron, France
| | - Valérie Hervieu
- Hospices Civils de Lyon, Biopathology of Tumours, GH Est (GHE) Hospital, Bron, France
| | - Brigitte Bancel
- Hospices Civils de Lyon, Biopathology of Tumours, GH Est (GHE) Hospital, Bron, France
| | - Mojgan Devouassoux
- Hospices Civils de Lyon, Department of Anatomopathology, Lyon-Sud Hospital, Lyon, France
| | - Brigitte Balme
- Hospices Civils de Lyon, Department of Anatomopathology, Lyon-Sud Hospital, Lyon, France
| | - David Meyronet
- Hospices Civils de Lyon, Biopathology of Tumours, GH Est (GHE) Hospital, Bron, France
| | | | - Jonathan Lopez
- Cancer Research Centre of Lyon, INSERM 1052, Centre National de la Recherche Scientifique (CNRS) 5286, University of Lyon, Lyon, France
- Hospices Civils de Lyon, Biochemistry and Molecular Biology Department, Lyon-Sud Hospital, Lyon, France
| | - Zhenyu Xu
- SOPHiA GENETICS, Saint-Sulpice, Switzerland
| |
Collapse
|
10
|
Fiani DJ, Émile JF, Istier L, Boutin AB, Tychyj C, Benzerdjeb N, Donzel M, Balme B, Traverse-Glehen A, Fontaine J. Une maladie de Rosai–Dorfman–Destombes de présentation laryngée trompeuse. Ann Pathol 2022; 42:475-480. [DOI: 10.1016/j.annpat.2022.03.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2021] [Revised: 03/01/2022] [Accepted: 03/03/2022] [Indexed: 10/15/2022]
|
11
|
Belkaïd S, Balme B, Harou O, Le Borgne de la Villandré J, Wirbel C, Dalle S, Grange F. Primary Cutaneous B-cell Lymphoma Leg-type Related to a Tumour Necrosis Factor Alpha Inhibitor. Acta Derm Venereol 2022; 102:adv00688. [DOI: 10.2340/actadv.v102.348] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Abstract is missing (Short communication)
Collapse
|
12
|
Darmon-Novello M, Adam J, Lamant L, Battistella M, Ortonne N, Balme B, de la Fouchardière A, Chaltiel L, Gerard E, Franchet C, Vergier B. Harmonization of PD-L1 immunohistochemistry and mRNA expression scoring in metastatic melanoma: a multicenter analysis. Histopathology 2022; 80:1091-1101. [PMID: 35322452 DOI: 10.1111/his.14651] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2021] [Revised: 02/21/2022] [Accepted: 03/21/2022] [Indexed: 11/29/2022]
Abstract
AIMS This multicenter study sought to harmonize programmed death ligand 1 (PD-L1) immunohistochemistry (IHC) data and melanoma scoring. To provide a reference for PD-L1 expression independent of the IHC protocol, PD-L1 mRNA expression was determined then compared to IHC. METHODS Standardized PD-L1 assays (22C3, 28-8, SP142, and SP263) and laboratory-developed tests (QR1 and 22C3) were evaluated on three IHC platforms using a training set of 7 cases. mRNA expression was determined via RNAscope (CD274/PD-L1 probe) and analyzed by image analysis. PD-L1 IHC findings were scored by seven blinded pathologists using the tumor proportion score (TPS), combined positive score (CPS), and MELscore. This method was validated by three blinded pathologists on 40 metastatic melanomas. RESULTS Concordances among various antibody/platforms were high across antibodies (ICC > 0.80 for CPS), except for SP142. Two levels of immunostaining intensities were observed: high (QR1 and SP263) and low (28-8, 22C3, and SP142). Reproducibilities across pathologists were higher for QR1 and SP263 (ICC ≥ 0.87 and ≥ 0.85 for TPS and CPS, respectively). QR1, SP263, and 28-8 showed the highest concordance with mRNA expression (ICC ≥ 0.81 for CPS). We developed a standardized method for PD-L1 immunodetection and scoring, tested on 40 metastatic melanomas. Concordances among antibodies were excellent for all criteria, and concordances among pathologists were better for the MELscore than for other scores. CONCLUSION Harmonization of PD-L1 staining and scoring in melanomas with good concordance is achievable using the PD-L1 IHC protocols applied to other cancers; this reproducible approach can simplify daily practice.
Collapse
Affiliation(s)
- M Darmon-Novello
- Department of Pathology, Bordeaux University Hospital and INSERM U1053, Bordeaux, France
| | - J Adam
- Department of Pathology, Gustave Roussy Institute, Paris, France
| | - L Lamant
- Department of Pathology, Oncopole University Hospital Toulouse, France
| | - M Battistella
- Department of Pathology, Hôpital Saint-Louis, AP-HP, Université de Paris, INSERM U976 HIPI, Paris, France
| | - N Ortonne
- Department of Pathology, University Hospital Henri Mondor, Creteil-, Paris, France
| | - B Balme
- Department of Pathology, University Hospital Lyon, France
| | | | - L Chaltiel
- Department of Biostatistics, Institut Claudius Regaud IUCT-O, Toulouse, France
| | - E Gerard
- Department of Dermatology, Bordeaux University Hospital, Bordeaux, France
| | - C Franchet
- Department of Pathology, Oncopole University Hospital Toulouse, France
| | - B Vergier
- Department of Pathology, Bordeaux University Hospital and INSERM U1053, Bordeaux, France
| |
Collapse
|
13
|
Plaschka M, Benboubker V, Grimont M, Berthet J, Tonon L, Lopez J, Le-Bouar M, Balme B, Tondeur G, de la Fouchardière A, Larue L, Puisieux A, Grinberg-Bleyer Y, Bendriss-Vermare N, Dubois B, Caux C, Dalle S, Caramel J. ZEB1 transcription factor promotes immune escape in melanoma. J Immunother Cancer 2022; 10:jitc-2021-003484. [PMID: 35288462 PMCID: PMC8921918 DOI: 10.1136/jitc-2021-003484] [Citation(s) in RCA: 31] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/31/2022] [Indexed: 12/30/2022] Open
Abstract
Background The efficacy of immunotherapies in metastatic melanoma depends on a robust T cell infiltration. Oncogenic alterations of tumor cells have been associated to T cell exclusion. Identifying novel cancer cell-intrinsic non-genetic mechanisms of immune escape, the targeting of which would reinstate T cell recruitment, would allow to restore the response to anti-programmed cell death protein 1 (PD-1) antibody therapy. The epithelial-to-mesenchymal transition (EMT)-inducing transcription factor ZEB1 is a major regulator of melanoma cell plasticity, driving resistance to mitogen-activated protein kinase (MAPK) targeted therapies. We thus wondered whether ZEB1 signaling in melanoma cells may promote immune evasion and resistance to immunotherapy. Methods We evaluated the putative correlation between ZEB1 expression in melanoma cells and the composition of the immune infiltrate in a cohort of 60 human melanoma samples by combining transcriptomic (RNA-sequencing) and seven-color spatial multi-immunofluorescence analyses. Algorithm-based spatial reconstitution of tumors allowed the quantification of CD8+, CD4+ T cells number and their activation state (PD-1, Ki67). ZEB1 gain-of-function or loss-of-function approaches were then implemented in syngeneic melanoma mouse models, followed by monitoring of tumor growth, quantification of immune cell populations frequency and function by flow cytometry, cytokines secretion by multiplex analyses. Chromatin-immunoprecipitation was used to demonstrate the direct binding of this transcription factor on the promoters of cytokine-encoding genes. Finally, the sensitivity to anti-PD-1 antibody therapy upon ZEB1 gain-of-function or loss-of-function was evaluated. Results Combined spatial and transcriptomic analyses of the immune infiltrates in human melanoma samples demonstrated that ZEB1 expression in melanoma cells is associated with decreased CD8+ T cell infiltration, independently of β-catenin pathway activation. ZEB1 ectopic expression in melanoma cells impairs CD8+ T cell recruitment in syngeneic mouse models, resulting in tumor immune evasion and resistance to immune checkpoint blockade. Mechanistically, we demonstrate that ZEB1 directly represses the secretion of T cell-attracting chemokines, including CXCL10. Finally, Zeb1 knock-out, by promoting CD8+ T cell infiltration, synergizes with anti-PD-1 antibody therapy in promoting tumor regression. Conclusions We identify the ZEB1 transcription factor as a key determinant of melanoma immune escape, highlighting a previously unknown therapeutic target to increase efficacy of immunotherapy in melanoma. Trial registration number NCT02828202.
Collapse
Affiliation(s)
- Maud Plaschka
- Cancer Cell Plasticity in Melanoma, Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon, INSERM 1052, CNRS 5286, Centre Léon Bérard, Lyon, France
| | - Valentin Benboubker
- Cancer Cell Plasticity in Melanoma, Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon, INSERM 1052, CNRS 5286, Centre Léon Bérard, Lyon, France
| | - Maxime Grimont
- Cancer Cell Plasticity in Melanoma, Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon, INSERM 1052, CNRS 5286, Centre Léon Bérard, Lyon, France
| | - Justine Berthet
- Cancer Immune Surveillance and Therapeutic Targeting, Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Lyon, France.,Laboratory of Immunotherapy of Cancer of Lyon (LICL), Lyon, France
| | - Laurie Tonon
- Fondation Synergie Lyon Cancer, Plateforme de bio-informatique Gilles Thomas, Centre Léon Bérard, Lyon, France
| | - Jonathan Lopez
- Cancer Cell Plasticity in Melanoma, Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon, INSERM 1052, CNRS 5286, Centre Léon Bérard, Lyon, France
| | - Myrtille Le-Bouar
- Dermatology Unit, Hospices Civils de Lyon, CH Lyon Sud, Pierre Bénite, France
| | - Brigitte Balme
- Dermatology Unit, Hospices Civils de Lyon, CH Lyon Sud, Pierre Bénite, France
| | - Garance Tondeur
- Dermatology Unit, Hospices Civils de Lyon, CH Lyon Sud, Pierre Bénite, France
| | - Arnaud de la Fouchardière
- Cancer Cell Plasticity in Melanoma, Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon, INSERM 1052, CNRS 5286, Centre Léon Bérard, Lyon, France
| | - Lionel Larue
- Institut Curie, PSL Research University, Paris, France
| | | | - Yenkel Grinberg-Bleyer
- Molecular Regulation of Immunity in Cancer, Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon, INSERM 1052, CNRS 5286, Centre Léon Bérard, Lyon, France
| | - Nathalie Bendriss-Vermare
- Cancer Immune Surveillance and Therapeutic Targeting, Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Lyon, France.,Laboratory of Immunotherapy of Cancer of Lyon (LICL), Lyon, France
| | - Bertrand Dubois
- Cancer Immune Surveillance and Therapeutic Targeting, Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Lyon, France.,Laboratory of Immunotherapy of Cancer of Lyon (LICL), Lyon, France
| | - Christophe Caux
- Cancer Immune Surveillance and Therapeutic Targeting, Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Lyon, France.,Laboratory of Immunotherapy of Cancer of Lyon (LICL), Lyon, France
| | - Stéphane Dalle
- Cancer Cell Plasticity in Melanoma, Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon, INSERM 1052, CNRS 5286, Centre Léon Bérard, Lyon, France.,Dermatology Unit, Hospices Civils de Lyon, CH Lyon Sud, Pierre Bénite, France
| | - Julie Caramel
- Cancer Cell Plasticity in Melanoma, Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon, INSERM 1052, CNRS 5286, Centre Léon Bérard, Lyon, France
| |
Collapse
|
14
|
Kelati A, Balme B, Chouvet B, Traverse-Glehen A, Tantot J, Harou O, Duru G, Debarbieux S, Dalle S, Thomas L. Significance of Primary Melanoma Regression on Local Infiltrate and Outcome. Dermatol Pract Concept 2022; 12:e2022034. [PMID: 35223178 PMCID: PMC8824592 DOI: 10.5826/dpc.1201a34] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/01/2021] [Indexed: 12/02/2022] Open
Abstract
Introduction The characteristics and the prognostic value of regression in primary melanomas are controversial. Objectives To further characterize “hot” and “cold” tumor’s stromas and to investigate the association between dermoscopy, pathology, and the prognostic implications of regression. Methods A 14-year-collection-based retrospective analysis was carried out on 40 patients with confirmed regressive melanomas. Results The extent of regression in dermoscopy was associated with the stage of the regression (P = 0.05) and with the MelanA patterns in histology (P = 0.02). Blue-gray and gray-brown color of the peppering (P = 0.01), and the eccentric, multifocal character of the dermoscopic regression (P = 0.05) were associated with “hot” stromas (CD8+, Granzym B+). Focal histologic regression (regressing melanomas) was associated with a good outcome (P < 0.001), while a complete regression (regressed melanomas) was associated with melanoma-related death (P < 0.001). “Hot” stromas (CD8+ were significantly associated with survival at 10 years (P = 0.044), while “hot” stromas (Granzyme B+) were associated with the locoregional extension (P = 0.016), and the initial distant metastasis (P = 0.016). Conclusions Dermoscopic features of regression in primary melanomas were associated with the stage of regression, its extent, and the “hot” or “cold” nature of the tumor stroma, with prognostic implications.
Collapse
Affiliation(s)
- Awatef Kelati
- Dermatology Department, Hôpital Universitaire Lyon Sud, Hospices Civils de Lyon. Pierre-Bénite, France
- Dermatology Department, Cheikh Khalifa International University Hospital, Mohammed VI University of Health Sciences (UM6SS), Casablanca, Morocco
| | - Brigitte Balme
- Anatomo-Pathology Department, Hôpital Universitaire Lyon Sud, Hospices Civils de Lyon. Pierre-Bénite, France
| | - Brigitte Chouvet
- Anatomo-Pathology Department, Hôpital Universitaire Lyon Sud, Hospices Civils de Lyon. Pierre-Bénite, France
| | - Alexandra Traverse-Glehen
- Anatomo-Pathology Department, Hôpital Universitaire Lyon Sud, Hospices Civils de Lyon. Pierre-Bénite, France
| | - Juliette Tantot
- Anatomo-Pathology Department, Hôpital Universitaire Lyon Sud, Hospices Civils de Lyon. Pierre-Bénite, France
| | - Olivier Harou
- Anatomo-Pathology Department, Hôpital Universitaire Lyon Sud, Hospices Civils de Lyon. Pierre-Bénite, France
| | - Gérard Duru
- Research director in the Claude Bernard University, Lyon, France
| | - Sebastien Debarbieux
- Dermatology Department, Hôpital Universitaire Lyon Sud, Hospices Civils de Lyon. Pierre-Bénite, France
| | - Stephane Dalle
- Dermatology Department, Hôpital Universitaire Lyon Sud, Hospices Civils de Lyon. Pierre-Bénite, France
- Lyon 1 University Lyon France
- Lyon Cancer Research Center, Centre Léon Bérard Lyon France
| | - Luc Thomas
- Dermatology Department, Hôpital Universitaire Lyon Sud, Hospices Civils de Lyon. Pierre-Bénite, France
- Lyon 1 University Lyon France
- Lyon Cancer Research Center, Centre Léon Bérard Lyon France
| |
Collapse
|
15
|
Kervarrec T, Pissaloux D, Poilane J, Tirode F, Tallet A, Collin C, Tallegas M, Berthon P, Gaboriaud P, Sohier P, Calonje E, Luzar B, Goto K, Cokelaere K, Lamant L, Balme B, Wild R, Neuville A, Deschamps L, Auberger E, Paumier V, Bonte H, Moulonguet I, Plantier F, Cales V, Pinsolle V, Roblet D, Dupuy F, Dallot A, Seris A, Jouary T, Houben R, Schrama D, Hesbacher S, Macagno N, Battistella M, Cribier B, Vergier B, Fouchardière A, Jullie M. Recurrent
FOXK1
::
GRHL
and
GPS2
::
GRHL
fusions in trichogerminoma. J Pathol 2022; 257:96-108. [DOI: 10.1002/path.5872] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Revised: 12/14/2021] [Accepted: 01/17/2022] [Indexed: 11/07/2022]
Affiliation(s)
- Thibault Kervarrec
- Department of Pathology Université de Tours, Centre Hospitalier Universitaire de Tours Tours France
- “Biologie des infections à polyomavirus” team, UMR INRA ISP 1282 Université de Tours Tours France
- CARADERM Network
| | - Daniel Pissaloux
- Department of Biopathology Center Léon Bérard Lyon France
- Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer Lyon France
| | - Jeremie Poilane
- Department of Pathology Université de Tours, Centre Hospitalier Universitaire de Tours Tours France
- Platform of Somatic Tumor Molecular Genetics Université de Tours, Centre Hospitalier Universitaire de Tours Tours France
- Department of Pathology Centre Hospitalier Universitaire de Angers Angers France
| | - Franck Tirode
- Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer Lyon France
| | - Anne Tallet
- Platform of Somatic Tumor Molecular Genetics Université de Tours, Centre Hospitalier Universitaire de Tours Tours France
| | - Christine Collin
- Platform of Somatic Tumor Molecular Genetics Université de Tours, Centre Hospitalier Universitaire de Tours Tours France
| | - Matthias Tallegas
- Department of Pathology Université de Tours, Centre Hospitalier Universitaire de Tours Tours France
- Platform of Somatic Tumor Molecular Genetics Université de Tours, Centre Hospitalier Universitaire de Tours Tours France
| | - Patricia Berthon
- “Biologie des infections à polyomavirus” team, UMR INRA ISP 1282 Université de Tours Tours France
| | - Pauline Gaboriaud
- “Biologie des infections à polyomavirus” team, UMR INRA ISP 1282 Université de Tours Tours France
| | - Pierre Sohier
- CARADERM Network
- Faculté de Médecine Paris Centre Santé University of Paris Paris France
- Department of Pathology Hôpital Cochin, AP‐HP Centre‐Université de Paris Paris France
| | - Eduardo Calonje
- Department of Dermatopathology St John's Institute of Dermatology, St Thomas's Hospital London UK
| | - Boštjan Luzar
- Institute of Pathology Medical Faculty University of Ljubljana Ljubljana Slovenia
| | - Keisuke Goto
- Department of Pathology Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital Tokyo Japan
- Department of Diagnostic Pathology Shizuoka Cancer Center Hospital, Sunto Japan
- Department of Diagnostic Pathology and Cytology Osaka International Cancer Institute Osaka Japan
- Department of Dermatology Hyogo Cancer Center Akashi Japan
| | | | - Laurence Lamant
- CARADERM Network
- Department of Pathology, CHU Toulouse, Institut Universitaire du Cancer Toulouse Oncopole Université Toulouse III Paul Sabatier Toulouse France
| | - Brigitte Balme
- CARADERM Network
- Department of Pathology Centre Hospitalier Universitaire de Lyon Lyon France
| | | | - Agnes Neuville
- Contades Office of Pathological Anatomy and Cytology Strasbourg France
| | - Lydia Deschamps
- CARADERM Network
- Department of Pathology, APHP Bichat Hospital Paris France
| | - Elisabeth Auberger
- Service d'anatomie et cytologie pathologiques Hopital Simone Veil Eaubonne France
| | | | | | | | - Françoise Plantier
- Department of Pathology Hôpital Cochin, AP‐HP Centre‐Université de Paris Paris France
- Cabinet Mathurin Moreau Paris France
| | - Valérie Cales
- Department of Pathology Centre hospitalier de Pau Pau France
| | - Vincent Pinsolle
- Department of plastic and reconstructive surgery Hôpital Haut‐Lévêque, Centre hospitalier universitaire de Bordeaux Pessac France
| | - Denis Roblet
- Department of Pathology Centre hospitalier d'Angouleme Saint Michel France
| | - Frantz Dupuy
- Laboratoire de cytologie et d'anatomie pathologiques», le Bouscat France
| | - Alexiane Dallot
- Centre national de Dermatopathologie‐La Roquette Paris France
| | | | - Thomas Jouary
- CARADERM Network
- Department of Dermatology Centre Hospitalier de Pau Pau France
| | - Roland Houben
- Department of Dermatology, Venereology and Allergology University Hospital Würzburg, Josef‐Schneider‐Straße 2 Würzburg Germany
| | - David Schrama
- Department of Dermatology, Venereology and Allergology University Hospital Würzburg, Josef‐Schneider‐Straße 2 Würzburg Germany
| | - Sonja Hesbacher
- Department of Dermatology, Venereology and Allergology University Hospital Würzburg, Josef‐Schneider‐Straße 2 Würzburg Germany
| | - Nicolas Macagno
- CARADERM Network
- Department of Biopathology Center Léon Bérard Lyon France
- Department of Pathology Timone University Hospital Marseille France
| | - Maxime Battistella
- CARADERM Network
- Department of Pathology, APHP Hôpital Saint Louis Université Paris 7 Paris France
| | - Bernard Cribier
- CARADERM Network
- Dermatology Clinic, Hôpitaux Universitaires & Université de Strasbourg, Hôpital Civil Strasbourg France
| | - Beatrice Vergier
- Department of Pathology, Hôpital Haut‐Lévêque, CHU de Bordeaux Pessac France
| | - Arnaud Fouchardière
- CARADERM Network
- Department of Biopathology Center Léon Bérard Lyon France
- Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer Lyon France
| | - Marie‐Laure Jullie
- CARADERM Network
- Department of Pathology, Hôpital Haut‐Lévêque, CHU de Bordeaux Pessac France
| |
Collapse
|
16
|
Battistella M, Balme B, Jullie ML, Zimmermann U, Carlotti A, Crinquette M, Frouin E, Macagno N, Ortonne N, Lamant L, de la Fouchardiere A, Aubriot-lorton MH, Durand L, Josselin N, Franck F, Chatelain D, Lemasson G, Algros MP, Durlach A, Machet MC, Courville P, Osio A, Seris A, Mortier L, Jouary T, Cribier B. Impact of expert pathology review in skin adnexal carcinoma diagnosis: Analysis of 2573 patients from the French CARADERM network. Eur J Cancer 2022; 163:211-221. [DOI: 10.1016/j.ejca.2021.11.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2021] [Revised: 10/19/2021] [Accepted: 11/26/2021] [Indexed: 11/30/2022]
|
17
|
Badrignans M, Oro S, Chong-Si-Tsaon A, Bagny K, Le Masson G, Legoupil D, Attencourt C, Dubois R, Faiz S, Beltzung F, D'Incan M, Koubaa W, Skrek S, Beltraminelli H, Balme B, Dalle S, Moustaghfir I, Chaby G, Deschamps T, Ortonne N. Pustular mycosis fungoides has a poor outcome: a clinico-pathological and longitudinal study of 36 cases. Eur J Cancer 2021; 156 Suppl 1:S23-S24. [PMID: 34649649 DOI: 10.1016/s0959-8049(21)00669-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- Marine Badrignans
- Département de Pathologie, Université Paris Est Creteil (UPEC) et IMRB INSERM U955 équipe Ortonne, hôpital Henri-Mondor, Paris, France
| | - Saskia Oro
- Service de dermatologie, CHU Henri-Mondor, Paris, France
| | | | - Kelly Bagny
- Services de Pathologie et Dermatologie, CHU Felix Guyon, Réunion, France
| | - Gilles Le Masson
- Services de Pathologie et Dermatologie, CHRU BREST, Brest, France
| | | | | | - Romain Dubois
- Services de Pathologie et Dermatologie, CHRU Claude Huriez, Lille, France
| | - Sarah Faiz
- Services de Pathologie et Dermatologie, CHRU Claude Huriez, Lille, France
| | - Fanny Beltzung
- Services de Pathologie et Dermatologie, CHU ESTAING, Clermont-Ferrand, France
| | - Michel D'Incan
- Services de Pathologie et Dermatologie, CHU ESTAING, Clermont-Ferrand, France
| | | | - Sergey Skrek
- Département De Dermatologie Et De Vénérologie, Saint-Petersbourg, Russia
| | | | - Brigitte Balme
- Centre De Pathologie et service de dermatologie, CH Lyon Sud, Lyon, France
| | - Stephane Dalle
- Centre De Pathologie et service de dermatologie, CH Lyon Sud, Lyon, France
| | | | - Guillaume Chaby
- Services de Pathologie et dermatologie, Hôpital Nord, Amiens, France
| | | | - Nicolas Ortonne
- Département de Pathologie, Université Paris Est Creteil (UPEC) et IMRB INSERM U955 équipe Ortonne, hôpital Henri-Mondor, Paris, France
| |
Collapse
|
18
|
Belkaid S, Balme B, Le Borgne De Lavillandre J, Dalle S, Grange F. Primary cutaneous B-cell lymphoma leg-type related to an anti-TNF-alpha therapy. Eur J Cancer 2021. [DOI: 10.1016/s0959-8049(21)00736-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
19
|
Ribereau-Gayon E, Heiblig M, Bourbon E, Sujobert P, Harou O, Theillac C, Poulalhon N, Balme B, Dalle S, Debarbieux S. Atypical extensive lupus tumidus-like eruption as an early presentation of VEXAS syndrome. Int J Dermatol 2021; 61:e89-e91. [PMID: 34587282 DOI: 10.1111/ijd.15916] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/11/2021] [Revised: 08/22/2021] [Accepted: 09/13/2021] [Indexed: 11/28/2022]
Affiliation(s)
- Emmanuel Ribereau-Gayon
- Dermatology Department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France
| | - Mael Heiblig
- Haematology Department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France
| | - Estelle Bourbon
- Biological Haematology Department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France
| | - Pierre Sujobert
- Biological Haematology Department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France
| | - Olivier Harou
- Pathology Department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France
| | - Claire Theillac
- Dermatology Department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France
| | - Nicolas Poulalhon
- Dermatology Department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France
| | - Brigitte Balme
- Pathology Department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France
| | - Stéphane Dalle
- Dermatology Department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France
| | - Sébastien Debarbieux
- Dermatology Department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France
| |
Collapse
|
20
|
Donzel M, Harou O, Skowron F, Dalle S, Descotes F, Balme B, Lopez J. Acral lentiginous melanoma with HER2/ErbB2 amplification. Eur J Dermatol 2021; 31:588-590. [PMID: 34642148 DOI: 10.1684/ejd.2021.4115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- Marie Donzel
- Department of Pathology, Lyon University Hospital, Hospices Civils de Lyon, Hôpital Lyon-Sud, Lyon, France
| | - Olivier Harou
- Department of Pathology, Lyon University Hospital, Hospices Civils de Lyon, Hôpital Lyon-Sud, Lyon, France
| | - François Skowron
- Department of Dermatology, Hôpitaux Drôme Nord, Romans-sur-Isère, France
| | - Stéphane Dalle
- Department of Dermatology, Lyon University Hospital, Hospices Civils de Lyon, Hôpital Lyon-Sud, Lyon, France, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France, Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, INSERM1052, CNRS5286, Lyon, France
| | - Françoise Descotes
- Department of Biochemistry and Molecular Biology, Lyon University Hospital, Hospices Civils de Lyon, Hôpital Lyon-Sud, Lyon, France
| | - Brigitte Balme
- Department of Pathology, Lyon University Hospital, Hospices Civils de Lyon, Hôpital Lyon-Sud, Lyon, France
| | - Jonathan Lopez
- Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France, Department of Biochemistry and Molecular Biology, Lyon University Hospital, Hospices Civils de Lyon, Hôpital Lyon-Sud, Lyon, France, Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, INSERM1052, CNRS5286, Lyon, France
| |
Collapse
|
21
|
Ribereau-Gayon E, Le Borgne De Lavillandre J, Deschamps T, Balme B, Harou O, Grange F. Syringotropic Mycosis Fungoides with Vasculopathic Ulcers and Expression of T-follicular-helper Cell Markers. Acta Derm Venereol 2021; 101:adv00569. [PMID: 34230976 PMCID: PMC9425591 DOI: 10.2340/00015555-3868] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
22
|
Donzel M, Balme B, Dalle S. Mycosis fungoides in patients with multiple sclerosis: A report of two cases. Ann Dermatol Venereol 2021; 148:275-277. [PMID: 34210534 DOI: 10.1016/j.annder.2021.06.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2021] [Revised: 04/07/2021] [Accepted: 06/01/2021] [Indexed: 11/26/2022]
Affiliation(s)
- M Donzel
- Institut de pathologie multisite, hospices civils de Lyon, hôpital Lyon Sud, 69310 Pierre-Bénite, France.
| | - B Balme
- Institut de pathologie multisite, hospices civils de Lyon, hôpital Lyon Sud, 69310 Pierre-Bénite, France
| | - S Dalle
- Service de dermatologie, hospices civils de Lyon, hôpital Lyon Sud, 69310 Pierre-Bénite, France; Université Claude-Bernard, Lyon 01, 69100 Lyon, France
| |
Collapse
|
23
|
Idoudi S, Bressac-de Paillerets B, Balme B, Bonnet-Dupeyron MN, Golmard L, Thomas L. Subungual squamous cell carcinoma in a BAP1 germline pathogenic variant carrier. J Eur Acad Dermatol Venereol 2021; 35:e665-e667. [PMID: 34014579 DOI: 10.1111/jdv.17372] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2021] [Revised: 04/18/2021] [Accepted: 04/29/2021] [Indexed: 11/27/2022]
Affiliation(s)
- S Idoudi
- Department of Dermatology, Centre Hospitalier Lyon Sud, Pierre Bénite, France
| | - B Bressac-de Paillerets
- Departement of Biopathology, Gustave Roussy, Villejuif, France.,Tumor Cell Dynamics, INSERM U1279, Villejuif, France
| | - B Balme
- Department of Anapathology, Centre Hospitalier Lyon Sud, Pierre Bénite, France
| | - M-N Bonnet-Dupeyron
- Department of Medical Genetics, Women Mothers and Children's Hospital, Lyon Hospices Civils, Lyon, France.,Department of Genetics, Valence Hospital's Center, Valence, France
| | - L Golmard
- Department of Genetics, PSL Research University, Institut Curie, Paris, France
| | - L Thomas
- Department of Dermatology, Centre Hospitalier Lyon Sud, Pierre Bénite, France.,Claude Bernard - Lyon 1 University, Lyon, France.,Lyons Cancer Research Center INSERM U1052 - CNRS UMR5286, Lyon, France
| |
Collapse
|
24
|
Bergqvist C, Beylot-Barry M, Ram-Wolff C, Vergier B, Bagot M, Battistella M, Dalle S, Balme B, Merlio JP, Durupt F, Le Corre Y, Bonnet N, Le Bozec P, Skowron F, Vivard-Wallee I, Dereure O, Brunet-Possenti F, Ingen-Housz-Oro S, Ortonne N. Lymphomatoid papulosis types D and E: a multicentre series of the French Cutaneous Lymphomas Study Group. Clin Exp Dermatol 2021; 46:1441-1451. [PMID: 33987864 DOI: 10.1111/ced.14730] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/10/2021] [Indexed: 11/30/2022]
Abstract
BACKGROUND Lymphomatoid papulosis (LyP) type D (LyP D) and type E (LyP E) have recently been described in small series of cases or isolated case reports. AIM To further describe the clinical and histological features of LyP D and E based on a retrospective multicentre study. METHODS The clinical and histopathological features of 29 patients with an initial diagnosis of LyP D or LyP E were retrospectively assessed using standardized forms. RESULTS After exclusion of 5 cases, 24 patients (14 LyP D, 10 LyP E) were enrolled in the study. The median follow-up was 2.5 years (range 1 month to 13 years). LyP D was characterized by multiple recurrent self-regressing small papules that developed central erosion or necrosis, whereas LyP E presented as papulonodular lesions that rapidly evolved into necrotic eschar-like lesions > 10 mm in size. Epidermal changes were more frequent in LyP D, whereas dermal infiltrates were deeper in LyP E. Anaplastic cytology was rare and the DUSP22 rearrangement was never observed. Two patients (8%) had an associated cutaneous lymphoma. CONCLUSION LyP D and E have distinct clinical findings and may be associated with other cutaneous lymphomas.
Collapse
Affiliation(s)
- C Bergqvist
- Department of, Dermatology, AP-HP, Hôpital Henri Mondor, Créteil, France
| | - M Beylot-Barry
- Department of, Dermatology, Bordeaux University Hospital, Bordeaux, France.,Cutaneous Lymphoma Oncogenesis Team, INSERM U1053 Bordeaux Research in Translational Oncology (BaRITOn), Bordeaux University, Bordeaux, France.,French Cutaneous Lymphomas Study Group, Paris, France
| | - C Ram-Wolff
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of, Dermatology, AP-HP, Hôpital Saint-Louis, Université de Paris, Paris, France
| | - B Vergier
- Department of, Pathology, Bordeaux University Hospital, Bordeaux, France.,French Cutaneous Lymphomas Study Group, Paris, France
| | - M Bagot
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of, Dermatology, AP-HP, Hôpital Saint-Louis, Université de Paris, Paris, France
| | - M Battistella
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of, Pathology, AP-HP, Hôpital Saint-Louis, Université de Paris, Paris, France
| | - S Dalle
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of, Dermatology, University Hospital of Lyon-Sud, Lyon, France
| | - B Balme
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of, Dermatology, University Hospital of Lyon-Sud, Lyon, France.,Department of, Pathology, University Hospital of Lyon-Sud, Lyon, France
| | - J P Merlio
- Cutaneous Lymphoma Oncogenesis Team, INSERM U1053 Bordeaux Research in Translational Oncology (BaRITOn), Bordeaux University, Bordeaux, France.,French Cutaneous Lymphomas Study Group, Paris, France
| | - F Durupt
- Department of Dermatology, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France
| | - Y Le Corre
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of Dermatology, CHU Angers, Angers, France
| | - N Bonnet
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of Dermatology, Hôpitaux de Marseille, Marseille, France
| | - P Le Bozec
- Department of Dermatology, AP-HP, Hôpital Beaujon, Clichy, France
| | - F Skowron
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of Dermatology, Centre Hospitalier de Valence, Valence, France
| | | | - O Dereure
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of Dermatology, CHU de Montpellier, Montpellier, France
| | - F Brunet-Possenti
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of Dermatology, AP-HP, Hôpital Bichat, Paris, France
| | - S Ingen-Housz-Oro
- Department of, Dermatology, AP-HP, Hôpital Henri Mondor, Créteil, France.,French Cutaneous Lymphomas Study Group, Paris, France
| | - N Ortonne
- Department of, Pathology, AP-HP, Hôpital Henri Mondor, Créteil, France.,French Cutaneous Lymphomas Study Group, Paris, France.,Paris Est Creteil University (UPEC) and IMRB, INSERM U955 Team Ortonne (NFL), Créteil, France
| |
Collapse
|
25
|
Menguy S, Mansour Y, Jullié ML, Augereau O, Ortonne N, Balme B, Battistella M, Lamant L, Beltzung F, Szablewski V, Gaulard P, Bagot M, Beylot-Barry M, Vergier B. [Impact of algorithms proposed by the Cutaneous Lymphoma French Study Group for diagnosis of cutaneous lymphoproliferations]. Ann Pathol 2021; 41:290-299. [PMID: 33926757 DOI: 10.1016/j.annpat.2021.03.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2020] [Revised: 03/11/2021] [Accepted: 03/22/2021] [Indexed: 10/21/2022]
Abstract
After a first diagnosis proposition, management of cutaneous lymphomas requires a systematic review by an expert pathologist and each case is presented to a multidisciplinary meeting in the setting of the French Study Group of Cutaneous Lymphomas to propose an adequate treatment. A retrospective study of the 2760 cutaneous lymphoproliferations retrieved between 2010 and 2011 were analyzed and demonstrated the interest of diagnostic algorithms we built with the group. The objective of our study was to compare two cohorts from 2010-2011 and 2015-2017 regarding the proportion of cases sent for validation or expertise, the concordance and mismatch rates and potential diagnostic issues using our diagnostic algorithms. Between 2015-2017, 5640 skin lymphoproliferation cases were examined. It appeared that Pathologists were more confident and effective in finding the right diagnosis. Indeed, the rate of concordant diagnosis increased from 57% to 67%. Moreover, in comparison with the 2010-2011 concordant cases sent for expertise, 73.5% of concordant cases were sent for validation in 2015-2017. 14% of cases remained discordant, mainly sent for expertise. Furthermore, half of questionable cases (26.3%) were resolved after expertise, and 12.1% cases remained unsolved. These priority cases are important to be presented at multidisciplinary meeting. The analysis of discordant and doubtful cases unveiled recurrent diagnostic problems for which we proposed appropriate diagnostic algorithms including large B cell lymphomas, CD4+ T cell lymphoproliferations, epidermotropic CD8+ T-cell lymphoproliferations and the differential diagnosis of mycosis fongoïdes/Sezary syndrome versus inflammatory dermatitis.
Collapse
Affiliation(s)
- Sarah Menguy
- Service de pathologie, hôpital Haut-Lévêque, CHU de Bordeaux, avenue Magellan, 33600 Pessac, France; Inserm U1053 BaRITOn équipe 3 Oncogenèse des lymphomes cutanés, université de Bordeaux, Bordeaux, France.
| | - Yara Mansour
- Service de pathologie, hôpital Haut-Lévêque, CHU de Bordeaux, avenue Magellan, 33600 Pessac, France
| | - Marie-Laure Jullié
- Service de pathologie, hôpital Haut-Lévêque, CHU de Bordeaux, avenue Magellan, 33600 Pessac, France
| | | | - Nicolas Ortonne
- Service de pathologie, hôpital Henri-Mondor, AP-HP, Créteil, France
| | | | | | - Laurence Lamant
- Service de pathologie, oncopole, CHU de Toulouse, Toulouse, France
| | - Fanny Beltzung
- Service de pathologie, CHU de Clermont-Ferrand, Clermont-Ferrand, France
| | | | - Philippe Gaulard
- Service de pathologie, hôpital Henri-Mondor, AP-HP, Créteil, France; Réseau INCa Lymphopath, France
| | - Martine Bagot
- Groupe français d'étude des lymphomes cutanés, France; Service de dermatologie, hôpital Saint-Louis, AP-HP, France
| | - Marie Beylot-Barry
- Inserm U1053 BaRITOn équipe 3 Oncogenèse des lymphomes cutanés, université de Bordeaux, Bordeaux, France; Service de dermatologie, hôpital Saint-André, CHU de Bordeaux, Bordeaux, France
| | - Béatrice Vergier
- Service de pathologie, hôpital Haut-Lévêque, CHU de Bordeaux, avenue Magellan, 33600 Pessac, France; Inserm U1053 BaRITOn équipe 3 Oncogenèse des lymphomes cutanés, université de Bordeaux, Bordeaux, France
| |
Collapse
|
26
|
Mangin MA, Lienhart A, Gouraud A, Roux S, Hodique F, Jouen F, Balme B, Dalle S, Debarbieux S. Onset of acquired haemophilia A after omalizumab treatment in severe bullous pemphigoid - a report on two cases successfully treated with mycophenolate mofetil. Ann Dermatol Venereol 2021; 148:57-59. [PMID: 33461795 DOI: 10.1016/j.annder.2020.09.577] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2020] [Revised: 08/24/2020] [Accepted: 09/30/2020] [Indexed: 10/22/2022]
Affiliation(s)
- M-A Mangin
- Service de dermatologie, hospices civils de Lyon, centre hospitalier Lyon-Sud, 69495 Pierre-Bénite cedex, France.
| | - A Lienhart
- Hospices civils de Lyon, groupement hospitalier Est, centre régional de traitement de l'Hémophilie, 69500 Bron cedex, France
| | - A Gouraud
- Pharmacovigilance, hospices civils de Lyon, centre hospitalier Lyon Sud, 69495 Pierre-Bénite cedex, France
| | - S Roux
- Service de maladies infectieuses et tropicales, hospices civils de Lyon, hôpital de la Croix Rousse, 69004 Lyon, France
| | - F Hodique
- Service de maladies infectieuses et tropicales, hospices civils de Lyon, hôpital de la Croix Rousse, 69004 Lyon, France
| | - F Jouen
- Biologie médicale, centre hospitalier de Rouen, hôpital Charles-Nicole, 76031 Rouen cedex, France
| | - B Balme
- Service d'anatomopathologie, hospices civils de Lyon, centre hospitalier Lyon Sud, 69495 Pierre-Bénite cedex, France
| | - S Dalle
- Service de dermatologie, hospices civils de Lyon, centre hospitalier Lyon-Sud, 69495 Pierre-Bénite cedex, France
| | - S Debarbieux
- Service de dermatologie, hospices civils de Lyon, centre hospitalier Lyon-Sud, 69495 Pierre-Bénite cedex, France
| |
Collapse
|
27
|
Menguy S, Mansour Y, Augereau O, Ortonne N, Balme B, Battistella M, Lamant L, Beltzung F, Szablewski V, Gaulard P, Bagot M, Beylot-Barry M, Vergier B. Impact des algorithmes du Groupe Français d’Étude des Lymphomes Cutanés sur le diagnostic anatomopathologique des lymphoproliférations cutanées. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
28
|
Badrignans M, Oro S, Chong-Si-Tsaon A, Bagny K, Le Masson G, Attencourt C, Legoupil D, Denamps J, Dubois R, Faiz S, Beltzung F, D’Incan M, Koubaa W, Hammami G, Beltraminelli H, Balme B, Dalle S, Dorel M, Nicolae A, Moustaghfir I, Skrek S, Deschamps T, Chaby G, Ortonne N. Le mycosis fongoïde pustuleux, une forme particulièrement agressive : étude clinicopathologique de 36 cas. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
29
|
Wirbel C, Marchetti A, Balme B, Dalle S. Vasculite leucocytoclasique sous pembrolizumab. Ann Dermatol Venereol 2020; 147:582-583. [DOI: 10.1016/j.annder.2020.06.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
30
|
Wirbel C, Milley S, Balme B, Dalle S. [Bullous pemphigoid under anti-PD1 therapy]. Ann Dermatol Venereol 2020; 147:795-797. [PMID: 32682608 DOI: 10.1016/j.annder.2020.06.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- C Wirbel
- Service de dermatologie, hôpital Lyon Sud, hôpital Lyon Sud, 165, chemin du Grand Revoyet, 69310 Pierre-Bénite, France
| | - S Milley
- Service de dermatologie, hôpital Lyon Sud, hôpital Lyon Sud, 165, chemin du Grand Revoyet, 69310 Pierre-Bénite, France
| | - B Balme
- Anatomo-pathologie, hôpital Lyon Sud, 165, chemin du Grand Revoyet, 69310 Pierre-Bénite, France
| | - S Dalle
- Service de dermatologie, hôpital Lyon Sud, hôpital Lyon Sud, 165, chemin du Grand Revoyet, 69310 Pierre-Bénite, France.
| |
Collapse
|
31
|
Gouillon L, Perier-Muzet M, Amini-Adle M, Poulalhon N, Debarbieux S, Boespflug A, Balme B, Depaepe L, Harou O, Lopez J, Bringuier PP, Ferraro-Peyret C, Maucort-Boulch D, Robinson P, Thomas L, Dalle S. Dermoscopic features in BRAF and NRAS primary cutaneous melanoma: association with peppering and blue-white veil. J Eur Acad Dermatol Venereol 2020; 34:e57-e59. [PMID: 31442328 DOI: 10.1111/jdv.15906] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- L Gouillon
- Hospices Civils de Lyon, Service de Dermatologie, Centre Hospitalier Lyon Sud, Pierre-Bénite, France
| | - M Perier-Muzet
- Hospices Civils de Lyon, Service de Dermatologie, Centre Hospitalier Lyon Sud, Pierre-Bénite, France
| | - M Amini-Adle
- Hospices Civils de Lyon, Service de Dermatologie, Centre Hospitalier Lyon Sud, Pierre-Bénite, France
| | - N Poulalhon
- Hospices Civils de Lyon, Service de Dermatologie, Centre Hospitalier Lyon Sud, Pierre-Bénite, France
| | - S Debarbieux
- Hospices Civils de Lyon, Service de Dermatologie, Centre Hospitalier Lyon Sud, Pierre-Bénite, France
| | - A Boespflug
- Hospices Civils de Lyon, Service de Dermatologie, Centre Hospitalier Lyon Sud, Pierre-Bénite, France
| | - B Balme
- Hospices Civils de Lyon, Service d'anatomie Pathologique, Centre Hospitalier Lyon Sud, Pierre-Bénite, France
| | - L Depaepe
- Hospices Civils de Lyon, Service d'anatomie Pathologique, Centre Hospitalier Lyon Sud, Pierre-Bénite, France
| | - O Harou
- Hospices Civils de Lyon, Service d'anatomie Pathologique, Centre Hospitalier Lyon Sud, Pierre-Bénite, France
| | - J Lopez
- Hospices Civils de Lyon, Service de Biologie et Biologie Moléculaire, Centre Hospitalier Lyon Sud, Pierre-Bénite, France
| | - P-P Bringuier
- Hospices Civils de Lyon, Service de Biologie Moléculaire, Hôpital Édouard Herriot, Lyon, France
| | - C Ferraro-Peyret
- Hospices Civils de Lyon, Service de Biologie Moléculaire, Hôpital Édouard Herriot, Lyon, France
| | - D Maucort-Boulch
- Hospices Civils de Lyon, Service de Statistiques, Université Lyon 1, Lyon, France
| | - P Robinson
- Hospices Civils de Lyon, Direction de la Recherche Clinique et Innovation, Lyon, France
| | - L Thomas
- Hospices Civils de Lyon, Service de Dermatologie, Centre Hospitalier Lyon Sud, Pierre-Bénite, France
| | - S Dalle
- Hospices Civils de Lyon, Service de Dermatologie, Centre Hospitalier Lyon Sud, Pierre-Bénite, France
| |
Collapse
|
32
|
Mangin M, Lienhart A, Gouraud A, Roux S, Hodique F, Balme B, Jouen F, Dalle S, Debarbieux S. Deux cas d’hémophilie A acquise associée à une pemphigoïde bulleuse traitée par omalizumab : coïncidence ou effet secondaire ? Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
33
|
Sonigo G, Battistella M, Beylot-Barry M, Oro S, Franck N, Barete S, Boulinguez S, Dereure O, Bonnet N, Socié G, Brice P, Boccara O, Bodemer C, Adamski H, D’Incan M, Ortonne N, Fraitag S, Brunet-Possenti F, Dalle S, Suarez F, Marcais A, Skowron F, Haidar D, Maubec E, Bohelay G, Laroche L, Mahé A, Birckel E, Bouaziz JD, Brocheriou I, Dubois R, Faiz S, Fadlallah J, Ram-Wolff C, Carlotti A, Bens G, Balme B, Vergier B, Laurent-Roussel S, Deschamps L, Carpentier O, Moguelet P, Hervé G, Comoz F, Le Gall F, Leverger G, Finon A, Augereau O, Bléchet C, Kerdraon R, lamant L, Tournier E, Franck F, Costes-Martineau V, Szablewski V, Taix S, Beschet I, Guérin F, Sepulveda F, Bagot M, De Saint-Basile G, Michonneau D, De Masson A. Étude clinique à long terme et mutations HAVCR2 chez 70 patients atteints de lymphome T sous cutané à type de panniculite. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
34
|
Jaulent L, Teysseire S, Poulalhon N, Balme B, Nancey S, Dalle S, Debarbieux S. Trois cas de rhinite croûteuse sur terrain de maladie de Crohn. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.487] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
35
|
Carlioz V, Balme B, Depaepe L, Thomas L. Dermoscopy of subungual acantholytic dyskeratotic acanthoma. Clin Exp Dermatol 2019; 45:355-356. [DOI: 10.1111/ced.14098] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/15/2019] [Indexed: 11/27/2022]
Affiliation(s)
- V. Carlioz
- Department of PathologyCentre Hospitalier de Lyon SudHospices Civils de LyonUniversité Claude Bernard Lyon 1 Pierre BéniteFrance
- Department of Dermatology Centre Hospitalier de Lyon Sud Hospices Civils de Lyon Université Claude Bernard Lyon 1 Pierre Bénite France
| | - B. Balme
- Department of PathologyCentre Hospitalier de Lyon SudHospices Civils de LyonUniversité Claude Bernard Lyon 1 Pierre BéniteFrance
| | - L. Depaepe
- Department of PathologyCentre Hospitalier de Lyon SudHospices Civils de LyonUniversité Claude Bernard Lyon 1 Pierre BéniteFrance
| | - L. Thomas
- Department of Dermatology Centre Hospitalier de Lyon Sud Hospices Civils de Lyon Université Claude Bernard Lyon 1 Pierre Bénite France
| |
Collapse
|
36
|
Boukerche H, Su ZZ, Emdad L, Baril P, Balme B, Thomas L, Randolph A, Valerie K, Sarkar D, Fisher PB. Editor's Note: mda-9/Syntenin: A Positive Regulator of Melanoma Metastasis. Cancer Res 2019; 79:5127. [DOI: 10.1158/0008-5472.can-19-2443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
37
|
Danset M, Milley S, Harou O, Vasseur D, Amini-Adle M, Thomas L, Dalle S, Balme B, Lopez J. Concomitant GNA11 and SF3B1 mutations in two cases of melanoma associated with blue naevus. Clin Exp Dermatol 2019; 45:123-126. [PMID: 31338849 DOI: 10.1111/ced.14036] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/18/2019] [Indexed: 11/28/2022]
Affiliation(s)
- M Danset
- Dermatology Unit, Lyon University Hospital, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Lyon, France.,Faculté de Médecine Lyon Est, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France
| | - S Milley
- Dermatology Unit, Lyon University Hospital, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Lyon, France.,Faculté de Médecine Lyon Est, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France
| | - O Harou
- Department of Pathology, Lyon University Hospital, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Lyon, France.,Faculté de Médecine Lyon Est, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France
| | - D Vasseur
- Faculté de Médecine Lyon Est, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.,Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.,Department of Biochemistry and Molecular Biology, Lyon University Hospital, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Lyon, France
| | - M Amini-Adle
- Dermatology Unit, Lyon University Hospital, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Lyon, France
| | - L Thomas
- Dermatology Unit, Lyon University Hospital, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Lyon, France.,Faculté de Médecine Lyon Est, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.,Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France
| | - S Dalle
- Dermatology Unit, Lyon University Hospital, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Lyon, France.,Faculté de Médecine Lyon Est, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.,Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France
| | - B Balme
- Department of Pathology, Lyon University Hospital, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Lyon, France
| | - J Lopez
- Faculté de Médecine Lyon Est, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.,Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.,Department of Biochemistry and Molecular Biology, Lyon University Hospital, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Lyon, France
| |
Collapse
|
38
|
Menguy S, Beylot‐Barry M, Parrens M, Ledard A, Frison E, Comoz F, Battistella M, Szablewski V, Balme B, Croue A, Franck F, Ortonne N, Tournier E, Lamant L, Carlotti A, De Muret A, Le Gall F, Lorton M, Merlio J, Vergier B. Primary cutaneous large B‐cell lymphomas: relevance of the 2017 World Health Organization classification: clinicopathological and molecular analyses of 64 cases. Histopathology 2019; 74:1067-1080. [DOI: 10.1111/his.13832] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2018] [Accepted: 01/31/2019] [Indexed: 12/26/2022]
Affiliation(s)
- Sarah Menguy
- Pathology Department University Hospital of Bordeaux Hôpital Haut‐Lévêque Bordeaux France
- INSERM U1053 Team 3 Oncogenesis of Cutaneous Lymphomas University of Bordeaux Bordeaux France
| | - Marie Beylot‐Barry
- INSERM U1053 Team 3 Oncogenesis of Cutaneous Lymphomas University of Bordeaux Bordeaux France
- Dermatology Department University Hospital of Bordeaux Hôpital Saint‐André Bordeaux France
| | - Marie Parrens
- Pathology Department University Hospital of Bordeaux Hôpital Haut‐Lévêque Bordeaux France
- INSERM U1053 Team 3 Oncogenesis of Cutaneous Lymphomas University of Bordeaux Bordeaux France
| | - Anne‐Pham Ledard
- INSERM U1053 Team 3 Oncogenesis of Cutaneous Lymphomas University of Bordeaux Bordeaux France
- Dermatology Department University Hospital of Bordeaux Hôpital Saint‐André Bordeaux France
| | - Eric Frison
- ISPED University Hospital of Bordeaux and University of Bordeaux Bordeaux France
| | - François Comoz
- Pathology Department University Hospital of Caen Hôpital Clémenceau Caen France
| | - Maxime Battistella
- Pathology Department University Hospital of Paris Hôpital Saint‐Louis APHP Paris France
| | - Vanessa Szablewski
- Pathology Department University Hospital of Montpellier Hôpital Gui‐de‐Chauliac Montpellier France
| | - Brigitte Balme
- Pathology Department University Hospital of Lyon‐Sud Lyon France
| | - Anne Croue
- Pathology Department University Hospital of Angers Angers France
| | - Frédéric Franck
- Pathology Department University Hospital of Clermont‐Ferrand Hôpital Estaing Clermont‐Ferrand France
| | - Nicolas Ortonne
- Pathology Department University Hospital of Paris Hôpital Henri‐Mondor APHP Créteil France
| | - Emilie Tournier
- Pathology Department Institut Universitaire du Cancer Toulouse Oncopôle Toulouse France
| | - Laurence Lamant
- Pathology Department Institut Universitaire du Cancer Toulouse Oncopôle Toulouse France
| | - Agnès Carlotti
- Pathology Department University Hospital of Paris Hôpital Cochin APHP Paris France
| | - Anne De Muret
- Pathology Department University Hospital of Tours Hôpital Trousseau Tours France
| | - François Le Gall
- Pathology Department University Hospital of Rennes Hôpital Pontchaillou Rennes France
| | | | - Jean‐Philippe Merlio
- INSERM U1053 Team 3 Oncogenesis of Cutaneous Lymphomas University of Bordeaux Bordeaux France
- Tumour Biology and Tumour Bank Department University Hospital of Bordeaux Hôpital Haut‐Lévêque Bordeaux France
| | - Béatrice Vergier
- Pathology Department University Hospital of Bordeaux Hôpital Haut‐Lévêque Bordeaux France
- INSERM U1053 Team 3 Oncogenesis of Cutaneous Lymphomas University of Bordeaux Bordeaux France
| |
Collapse
|
39
|
Menguy S, Beylot-Barry M, Parrens M, Ledard AP, Frison E, Comoz F, Battistella M, Szablewski V, Balme B, Croue A, Franck F, Ortonne N, Tournier E, Lamant L, Carlotti A, De Muret A, Le Gall F, Lorton MH, Merlio JP, Vergier B. Primary cutaneous large B-cell lymphomas: relevance of the 2017 World Health Organization classification: clinicopathological and molecular analyses of 64 cases. Eur J Cancer 2019. [DOI: 10.1016/s0959-8049(19)30565-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
40
|
Bontoux C, De Masson A, Boccara O, Bodemer C, Fraitag S, Balme B, Franck N, Carlotti A, Comoz F, Verneuil L, Brasme JF, Duplan M, Croué A, Templier I, Beltraminelli H, Dereure O, Szablewski V, Thevenin C, Boulinguez S, Viraben R, Tournier E, Lamant L, Ortonne N, Ingen-Housz-Oro S, Beckerich F, Grange F, Durlach A, Amatore F, Frouin E, McIntyre E, Asnafi V, Kim R, Clappier E, Soulier J, Boissel N, Dombret H, Bagot M, Battistella M. Clinical aspects and outcome of lymphoblastic leukemia/lymphoma with cutaneous involvement. Eur J Cancer 2019. [DOI: 10.1016/s0959-8049(19)30538-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
41
|
Boespflug A, Debarbieux S, Depaepe L, Chouvet B, Maucort-Boulch D, Dalle S, Balme B, Thomas L. Reply to "Comment on 'Association of subungual melanoma and subungual squamous cell carcinoma: A case series'". J Am Acad Dermatol 2018; 80:e63-e64. [PMID: 30393092 DOI: 10.1016/j.jaad.2018.10.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2018] [Revised: 10/22/2018] [Accepted: 10/24/2018] [Indexed: 11/19/2022]
Affiliation(s)
- Amélie Boespflug
- Hospices Civils de Lyon, Dermatology Unit, Lyon, France; Department of Medicine, Claude Bernard Lyon-1 University, INSERM 1052, CNRS 5286, Centre Leon Berard, Lyon, France; Cancer Research Center of Lyon, Claude Bernard Lyon-1 University, INSERM 1052, CNRS 5286, Centre Leon Berard, Lyon, France
| | | | | | | | - Delphine Maucort-Boulch
- Laboratoire de Biométrie et Biologie Evolutive, CNRS UMR 5558, Biostatistique-Santé Team, Université Lyon 1, Villeurbanne, France
| | - Stéphane Dalle
- Hospices Civils de Lyon, Dermatology Unit, Lyon, France; Department of Medicine, Claude Bernard Lyon-1 University, INSERM 1052, CNRS 5286, Centre Leon Berard, Lyon, France; Cancer Research Center of Lyon, Claude Bernard Lyon-1 University, INSERM 1052, CNRS 5286, Centre Leon Berard, Lyon, France
| | | | - Luc Thomas
- Hospices Civils de Lyon, Dermatology Unit, Lyon, France; Department of Medicine, Claude Bernard Lyon-1 University, INSERM 1052, CNRS 5286, Centre Leon Berard, Lyon, France; Cancer Research Center of Lyon, Claude Bernard Lyon-1 University, INSERM 1052, CNRS 5286, Centre Leon Berard, Lyon, France.
| |
Collapse
|
42
|
Amini-Adle M, Balme B, Locatelli-Sanchez M, Souquet PJ, Dalle S. [Oral and mucosal lichenoid drug eruption under anti-PD-1]. Ann Dermatol Venereol 2018; 145:725-727. [PMID: 30126642 DOI: 10.1016/j.annder.2018.07.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- M Amini-Adle
- Immucare, service de dermatologie, centre hospitalier Lyon-Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite cedex, France
| | - B Balme
- Service d'anatomo pathologie, centre hospitalier Lyon-Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite cedex, France
| | - M Locatelli-Sanchez
- Service de pneumologie, centre hospitalier Lyon-Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite cedex, France
| | - P-J Souquet
- Service de pneumologie, centre hospitalier Lyon-Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite cedex, France
| | - S Dalle
- Immucare, service de dermatologie, centre hospitalier Lyon-Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite cedex, France.
| |
Collapse
|
43
|
Theillac C, Cinotti E, Malvehy J, Ronger Savle S, Balme B, Robinson P, Perrot JL, Douchet C, Biron Schneider AC, Alos L, Garcia A, Barreiro A, Labeille B, Duru G, Dalle S, Thomas L, Debarbieux S. Evaluation of large clinically atypical vulvar pigmentation with RCM: atypical melanosis or early melanoma? J Eur Acad Dermatol Venereol 2018; 33:84-92. [PMID: 29920797 DOI: 10.1111/jdv.15141] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2018] [Accepted: 05/22/2018] [Indexed: 11/26/2022]
Abstract
BACKGROUND Vulvar melanosis can occasionally be clinically challenging by mimicking an early melanoma. OBJECTIVE To report our experience of initial evaluation and follow-up in this peculiar subset of vulvar melanosis using reflectance confocal microscopy (RCM). METHODS We retrospectively evaluated 18 consecutive cases referred for atypical vulvar pigmentation or for which melanoma was considered and that underwent both RCM examination and histopathological assessment. In 13 cases with available dermoscopic pictures, RCM classification was compared to dermoscopic diagnosis, and in all cases, the density of melanocytes was evaluated on biopsies using MelanA immunostaining. RESULTS Among the 18 atypical pigmented lesions, 17 vulvar melanosis and one melanoma were histologically determined. RCM concluded a benign vulvar melanosis in 10 of 17 cases, whereas dermoscopy did so in three of 12 cases. RCM identified the only early malignant lentiginous melanoma. In several cases of vulvar melanosis, RCM could identify foci of melanocytic hyperplasia in an otherwise benign pattern. CONCLUSIONS In this clinically and dermoscopically challenging subset of vulvar pigmentations, RCM appears relevant for initial extensive evaluation, especially to target initial biopsy sampling, and to perform non-invasive monitoring of foci of melanocytic hyperplasia.
Collapse
Affiliation(s)
- C Theillac
- Dermatology Department, Centre Hospitalier de Lyon Sud, Hospices civils de Lyon, Université Claude Bernard Lyon 1, Pierre Bénite, France
| | - E Cinotti
- Dermatology Department, University Hospital of Saint-Etienne, Saint-Etienne, France.,Pour le Groupe Imagerie Cutanée Non Invasive de la Société Française de Dermatologie, Paris, France
| | - J Malvehy
- Dermatology Department, Hospital Clinic of Barcelona, University of Barcelona, IDIBAPS, Barcelona, Spain
| | - S Ronger Savle
- Dermatology Department, Centre Hospitalier de Lyon Sud, Hospices civils de Lyon, Université Claude Bernard Lyon 1, Pierre Bénite, France
| | - B Balme
- Pathology Department, Centre Hospitalier de Lyon Sud, Lyon, France
| | - P Robinson
- DRCI, Hospices Civils de Lyon, Lyon, France
| | - J L Perrot
- Dermatology Department, University Hospital of Saint-Etienne, Saint-Etienne, France.,Pour le Groupe Imagerie Cutanée Non Invasive de la Société Française de Dermatologie, Paris, France
| | - C Douchet
- Pathology Department, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - A C Biron Schneider
- Dermatology Department, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - L Alos
- Pathology Department, Hospital Clinic of Barcelona, Barcelona, Spain
| | - A Garcia
- Pathology Department, Hospital Clinic of Barcelona, Barcelona, Spain
| | - A Barreiro
- Dermatology Department, Hospital Clinic of Barcelona, University of Barcelona, IDIBAPS, Barcelona, Spain
| | - B Labeille
- Dermatology Department, University Hospital of Saint-Etienne, Saint-Etienne, France.,Pour le Groupe Imagerie Cutanée Non Invasive de la Société Française de Dermatologie, Paris, France
| | - G Duru
- Department of Biostatistics, Université Claude Bernard Lyon 1, Villeurbanne, France
| | - S Dalle
- Dermatology Department, Centre Hospitalier de Lyon Sud, Hospices civils de Lyon, Université Claude Bernard Lyon 1, Pierre Bénite, France
| | - L Thomas
- Dermatology Department, Centre Hospitalier de Lyon Sud, Hospices civils de Lyon, Université Claude Bernard Lyon 1, Pierre Bénite, France
| | - S Debarbieux
- Dermatology Department, Centre Hospitalier de Lyon Sud, Hospices civils de Lyon, Université Claude Bernard Lyon 1, Pierre Bénite, France.,Pour le Groupe Imagerie Cutanée Non Invasive de la Société Française de Dermatologie, Paris, France
| |
Collapse
|
44
|
Carlioz V, Faivre C, Balme B, Joosten H, Pradier T, Skowron F. [Zosteriform cutaneous metastasis in melanoma]. Ann Dermatol Venereol 2018; 145:113-115. [PMID: 29217081 DOI: 10.1016/j.annder.2017.10.015] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2017] [Revised: 07/20/2017] [Accepted: 10/31/2017] [Indexed: 11/21/2022]
Abstract
INTRODUCTION Cutaneous metastases are common in patients with malignant melanoma. In rare cases, they are distributed on a dermatome, in which case they are known as zosteriform metastases. OBSERVATION We report the case of a patient with zosteriform metastasis of a malignant melanoma, progressing unfavourably despite surgical excision and immunotherapy. DISCUSSION The physiopathology of this condition continues to be poorly understood.
Collapse
Affiliation(s)
- V Carlioz
- Service de dermatologie, centre hospitalier de Valence, 179, boulevard Maréchal-Juin, 26000 Valence, France.
| | - C Faivre
- Service de dermatologie, centre hospitalier de Valence, 179, boulevard Maréchal-Juin, 26000 Valence, France
| | - B Balme
- Service de dermato-pathologie, centre hospitalier Lyon Sud, 69495 Pierre-Benite, France
| | - H Joosten
- Service d'oncologie, centre hospitalier de Valence, 179, boulevard Maréchal-Juin, 26000 Valence, France
| | - T Pradier
- Service de chirurgie viscérale, centre hospitalier de Valence, 179, boulevard Maréchal-Juin, 26000 Valence, France
| | - F Skowron
- Service de dermatologie, centre hospitalier de Valence, 179, boulevard Maréchal-Juin, 26000 Valence, France
| |
Collapse
|
45
|
Collinge E, Tigaud I, Balme B, Gerland LM, Sujobert P, Carlioz V, Salles G, Thomas X, Paubelle E. Case report: Purulent transformation of granulocytic sarcoma: An unusual pattern of differentiation in acute promyelocytic leukemia. Medicine (Baltimore) 2018; 97:e9657. [PMID: 29465554 PMCID: PMC5841987 DOI: 10.1097/md.0000000000009657] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
RATIONALE Acute promyelocytic leukemia (APL) is a curable subtype of acute myeloid leukemia. APL is currently treated with combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) resulting in the induction of apoptosis and differentiation of the leukemic cells. Differentiation syndrome (so-called ATRA syndrome) is the main life-threatening complication of induction therapy with these differentiating agents. PATIENT CONCERNS Herein, we report the case of a 49-year-old woman diagnosed with APL with, concomitantly, a bulky cutaneous lesion of 10 cm diameter with a red-to-purple background and a necrotic center, localized on her abdomen. DIAGNOSES After 10 days of treatment, the cutaneous lesion became purulent. Fluorescence in situ hybridization (FISH) analysis performed on this pus confirmed the presence of malignant features in the involved granulocytes proving their origin from the differentiation of leukemic APL cells, as all the analyzed nuclei showed 2 promyelocytic leukemia (PML)-retinoic acid receptor-a (RARA) fusions signals. INTERVENTION The association by ATRA and ATO was continued. OUTCOME Eventually, the evolution was favorable with healing in three weeks. LESSONS This case report therefore highlights the differentiation phenomenon of promyelocytic blasts within promyelocytic sarcoma with the ATRA-ATO combination and the efficacy of this drug association in resolving both the malignant sarcoma and a secondary local infection.
Collapse
Affiliation(s)
- Elodie Collinge
- Department of Hematology, CHU UCL Namur, Belgium
- Department of Hematology
| | | | | | | | | | - Violette Carlioz
- Department of Dermatology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud
| | | | | | - Etienne Paubelle
- Laboratory of Hematology
- LBMC, ENS, CNRS UMR5239, Faculté de Médecine Lyon Sud, Pierre-Bénite, France
| |
Collapse
|
46
|
Laffay L, Depaepe L, D'hombres A, Balme B, Thomas L, De Bari B. Histological Features and Treatment Approach of Trichoblastic Carcinomas: From a Case Report to a Review of the Literature. Tumori 2018. [DOI: 10.1177/030089161209800222] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background Trichoblastic carcinoma (or malignant trichoblastoma) is a rare malignant cancer of adnexal structures with morphological features that in some cases are reminiscent of a trichoblastoma. Trichoblastic carcinoma is underdiagnosed as it is a rather recent entity which is still not recognized as such by all pathologists. The differential diagnosis with basal cell carcinoma is often difficult to make and the optimal treatment has not yet been established. Case report We report the case of a 43-year-old patient who underwent surgical excision and adjuvant radiotherapy for a growing mass of 40 × 48 mm located in the lumbar right paraspinal skin. The pathological findings demonstrated a trichoblastic carcinoma. The clinicopathological profile, the histogenesis, and the difficulties related to the histopathological diagnosis and treatment of this rare entity are discussed in this article. Conclusion Although the published reports on this disease are few, surgery should be considered the standard therapeutic approach for trichoblastic carcinomas. Selected cases presenting clinical features of local aggressiveness can safely be treated with adjuvant irradiation to improve local control. However, acute and particularly late toxicities need to be taken into account in the decision.
Collapse
Affiliation(s)
- Lisa Laffay
- Department of Radiotherapy-Oncology, Centre Hospitalier Lyon-Sud, Pierre Bénite cedex
| | - Lauriane Depaepe
- Department of Pathology, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre Bénite cedex, France
| | - Anne D'hombres
- Department of Radiotherapy-Oncology, Centre Hospitalier Lyon-Sud, Pierre Bénite cedex
| | - Brigitte Balme
- Department of Pathology, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre Bénite cedex, France
| | - Luc Thomas
- Department of Dermatology, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre Bénite cedex, France
| | - Berardino De Bari
- Department of Radiotherapy-Oncology, Centre Hospitalier Lyon-Sud, Pierre Bénite cedex
| |
Collapse
|
47
|
Hurabielle C, Sbidian E, Beltraminelli H, Bouchindhomme B, Chassagne-Clément C, Balme B, Bossard C, Delfau-Larue MH, Wolkenstein P, Chosidow O, Cordonnier C, Toma A, Pautas C, Ortonne N. Eruption of lymphocyte recovery with atypical lymphocytes mimicking a primary cutaneous T-cell lymphoma: a series of 12 patients. Hum Pathol 2018; 71:100-108. [DOI: 10.1016/j.humpath.2017.10.018] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/13/2017] [Revised: 10/05/2017] [Accepted: 10/10/2017] [Indexed: 12/18/2022]
|
48
|
Picard C, Fontaine J, Chouvet B, Balme B, Traverse-Glehen A. [The key role of the pathologist in the diagnosis of syphilis: A case report]. Ann Pathol 2017; 38:64-67. [PMID: 29277436 DOI: 10.1016/j.annpat.2017.10.014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2016] [Revised: 10/11/2017] [Accepted: 10/24/2017] [Indexed: 11/25/2022]
Abstract
Syphilis is a resurging sexually transmitted infection linked to Treponema Pallidum. Syphilitic lymphadenitis can be present during the 3 stages of the disease. Its histological diagnosis remains challenging for the pathologist given its possible misleading aspect and its ability to mimic as well as reactional as tumoral conditions. We report the case of an HIV-infected young patient referred for suspicion of an aggressive lymphoma. Histological and immunohistochemical analysis of cervical lymphadenopathy revealed secondary syphilis.
Collapse
Affiliation(s)
- Cécile Picard
- Hospices civils de Lyon, institut de pathologie multisite, centre de biologie sud, centre hospitalier, 165, chemin du Grand-Revoyet, 69310 Pierre-Bénite, France; Université de Lyon 1, 8, avenue Rockefeller, 69003 Lyon, France.
| | - Juliette Fontaine
- Hospices civils de Lyon, institut de pathologie multisite, centre de biologie sud, centre hospitalier, 165, chemin du Grand-Revoyet, 69310 Pierre-Bénite, France; Université de Lyon 1, 8, avenue Rockefeller, 69003 Lyon, France
| | - Brigitte Chouvet
- Hospices civils de Lyon, institut de pathologie multisite, centre de biologie sud, centre hospitalier, 165, chemin du Grand-Revoyet, 69310 Pierre-Bénite, France; Université de Lyon 1, 8, avenue Rockefeller, 69003 Lyon, France
| | - Brigitte Balme
- Hospices civils de Lyon, institut de pathologie multisite, centre de biologie sud, centre hospitalier, 165, chemin du Grand-Revoyet, 69310 Pierre-Bénite, France; Université de Lyon 1, 8, avenue Rockefeller, 69003 Lyon, France
| | - Alexandra Traverse-Glehen
- Hospices civils de Lyon, institut de pathologie multisite, centre de biologie sud, centre hospitalier, 165, chemin du Grand-Revoyet, 69310 Pierre-Bénite, France; Université de Lyon 1, 8, avenue Rockefeller, 69003 Lyon, France
| |
Collapse
|
49
|
Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dréno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ, Weber JS, Eggermont AM, Zitvogel L. Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat Commun 2017; 8:592. [PMID: 28928380 PMCID: PMC5605517 DOI: 10.1038/s41467-017-00608-2] [Citation(s) in RCA: 146] [Impact Index Per Article: 20.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2017] [Accepted: 07/10/2017] [Indexed: 12/31/2022] Open
Abstract
Immune checkpoint blockers (ICB) have become pivotal therapies in the clinical armamentarium against metastatic melanoma (MMel). Given the frequency of immune related adverse events and increasing use of ICB, predictors of response to CTLA-4 and/or PD-1 blockade represent unmet clinical needs. Using a systems biology-based approach to an assessment of 779 paired blood and tumor markers in 37 stage III MMel patients, we analyzed association between blood immune parameters and the functional immune reactivity of tumor-infiltrating cells after ex vivo exposure to ICB. Based on this assay, we retrospectively observed, in eight cohorts enrolling 190 MMel patients treated with ipilimumab, that PD-L1 expression on peripheral T cells was prognostic on overall and progression-free survival. Moreover, detectable CD137 on circulating CD8+ T cells was associated with the disease-free status of resected stage III MMel patients after adjuvant ipilimumab + nivolumab (but not nivolumab alone). These biomarkers should be validated in prospective trials in MMel.The clinical management of metastatic melanoma requires predictors of the response to checkpoint blockade. Here, the authors use immunological assays to identify potential prognostic/predictive biomarkers in circulating blood cells and in tumor-infiltrating lymphocytes from patients with resected stage III melanoma.
Collapse
Affiliation(s)
- N Jacquelot
- INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.,University Paris-Saclay, Kremlin Bicêtre, 94 276, France.,Gustave Roussy Cancer Campus, Villejuif, 94800, France
| | - M P Roberti
- INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.,Gustave Roussy Cancer Campus, Villejuif, 94800, France
| | - D P Enot
- Gustave Roussy Cancer Campus, Villejuif, 94800, France.,Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, 94800, France
| | - S Rusakiewicz
- INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.,Gustave Roussy Cancer Campus, Villejuif, 94800, France.,CIC1428, Gustave Roussy Cancer Campus, Villejuif, 94800, France
| | - N Ternès
- University Paris-Saclay, Kremlin Bicêtre, 94 276, France.,Gustave Roussy Cancer Campus, Villejuif, 94800, France.,Gustave Roussy, Université Paris-Saclay, Service de Biostatistique et d'Epidémiologie, Villejuif, F-94805, France
| | - S Jegou
- Saint Antoine Hospital, INSERM ERL 1157-CNRS UMR 7203, Paris, 75005, France
| | - D M Woods
- Laura & Isaac Perlmutter Cancer Center, New York University Medical Center, New York, NY, 10016, USA
| | - A L Sodré
- Laura & Isaac Perlmutter Cancer Center, New York University Medical Center, New York, NY, 10016, USA
| | - M Hansen
- Center for Cancer Immune Therapy, Department of Hematology and Oncology, Copenhagen University Hospital, Herlev, DK-2730, Denmark
| | - Y Meirow
- The Lautenberg Center for General and Tumor Immunology, BioMedical Research institute Israel Canada of the Faculty of Medicine, The Hebrew University Hadassah Medical School, Jerusalem, 91120, Israel
| | - M Sade-Feldman
- The Lautenberg Center for General and Tumor Immunology, BioMedical Research institute Israel Canada of the Faculty of Medicine, The Hebrew University Hadassah Medical School, Jerusalem, 91120, Israel
| | - A Burra
- Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, 94143, USA
| | - S S Kwek
- Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, 94143, USA
| | - C Flament
- INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.,University Paris-Saclay, Kremlin Bicêtre, 94 276, France.,Gustave Roussy Cancer Campus, Villejuif, 94800, France.,CIC1428, Gustave Roussy Cancer Campus, Villejuif, 94800, France
| | - M Messaoudene
- INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.,Gustave Roussy Cancer Campus, Villejuif, 94800, France
| | - C P M Duong
- INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.,Gustave Roussy Cancer Campus, Villejuif, 94800, France
| | - L Chen
- Department of Immunobiology, Yale School of Medicine, 10 Amistad Street, New Haven, CT, 06519, USA
| | - B S Kwon
- Eutilex, Suite# 1401 Daeryung Technotown 17 Gasan Digital 1-ro 25, Geumcheon-gu, Seoul, 08594, Korea.,Section of Clinical Immunology, Allergy, and Rheumatology, Department of Medicine, Tulane University Health Sciences Center, New Orleans, LA, 70112, USA
| | - A C Anderson
- Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA
| | - V K Kuchroo
- Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA
| | - B Weide
- Department of Dermatology, University Medical Center Tübingen, Tübingen, 72076, Germany
| | - F Aubin
- Université de Franche Comté, EA3181, SFR4234, Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Besançon, 25000, France
| | - C Borg
- Department of Medical Oncology, University Hospital of Besancon, 3 Boulevard Alexander Fleming, Besancon, F-25030, France.,Clinical Investigational Centre, CIC-1431, University Hospital of Besançon, Besançon, 25030, France.,INSERM U1098, University of Franche-Comté, Besançon, 25020, France
| | - S Dalle
- Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon and University Claude Bernard Lyon 1, Lyon, 69000, France.,Centre de Recherche en Cancérologie de Lyon, Lyon, 69000, France
| | - O Beatrix
- Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon and University Claude Bernard Lyon 1, Lyon, 69000, France
| | - M Ayyoub
- INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.,Gustave Roussy Cancer Campus, Villejuif, 94800, France
| | - B Balme
- Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon and University Claude Bernard Lyon 1, Lyon, 69000, France.,Department of Pathology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Lyon, 69000, France
| | - G Tomasic
- Gustave Roussy Cancer Campus, Villejuif, 94800, France.,Department of Pathology, Gustave Roussy Cancer Campus, Villejuif, 94800, France
| | - A M Di Giacomo
- Medical Oncology and Immunotherapy Division, University Hospital of Siena, Viale Bracci, 14, Siena, 53100, Italy
| | - M Maio
- Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Instituto Toscano Tumori, Siena, 53100, Italy
| | - D Schadendorf
- Department of Dermatology, University Hospital, University Duisburg-Essen, Essen, Germany & German Cancer Consortium (DKTZ), Heidelberg, D-69120, Germany
| | - I Melero
- Division of Gene Therapy and Hepatology, Centre for Applied Medical Research, Pamplona, 31008, Spain.,Oncology Department, University Clinic of Navarra, Pamplona, 31008, Spain.,Centro de Investigación cBiomedica en Red de Oncologia, Pamplona, 31008, Spain
| | - B Dréno
- Department of Onco-dermatology, CIC Biotherapy, INSERM U1232, CHU Nantes, Nantes, 44000, France
| | - A Khammari
- Department of Onco-dermatology, CIC Biotherapy, INSERM U1232, CHU Nantes, Nantes, 44000, France
| | - R Dummer
- Department of Dermatology, University Hospital Zürich and University of Zürich, Zürich, 8091, Switzerland
| | - M Levesque
- Department of Dermatology, University Hospital Zürich and University of Zürich, Zürich, 8091, Switzerland
| | - Y Koguchi
- Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR, 97213, USA
| | - L Fong
- Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, 94143, USA
| | - M Lotem
- Sharett Institute of Oncology, Hadassah Medical Organization, Jerusalem, 91120, Israel
| | - M Baniyash
- The Lautenberg Center for General and Tumor Immunology, BioMedical Research institute Israel Canada of the Faculty of Medicine, The Hebrew University Hadassah Medical School, Jerusalem, 91120, Israel
| | - H Schmidt
- Department of Oncology, Aarhus University Hospital, Aarhus, DK-8200, Denmark
| | - I M Svane
- Center for Cancer Immune Therapy, Department of Hematology and Oncology, Copenhagen University Hospital, Herlev, DK-2730, Denmark
| | - G Kroemer
- Gustave Roussy Cancer Campus, Villejuif, 94800, France.,Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, 94800, France.,INSERM U1138, Centre de Recherche des Cordeliers, Paris, 75006, France.,Equipe 11 labellisée par la Ligue contre le Cancer, Centre de Recherche des Cordeliers, Paris, 75006, France.,Université Paris Descartes, Sorbonne Paris Cité, Paris, 75006, France.,Université Pierre et Marie Curie, Paris, 75005, France.,Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, 75015, France
| | - A Marabelle
- INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.,Gustave Roussy Cancer Campus, Villejuif, 94800, France.,CIC1428, Gustave Roussy Cancer Campus, Villejuif, 94800, France
| | - S Michiels
- Gustave Roussy Cancer Campus, Villejuif, 94800, France.,Gustave Roussy, Université Paris-Saclay, Service de Biostatistique et d'Epidémiologie, Villejuif, F-94805, France
| | - A Cavalcanti
- Gustave Roussy Cancer Campus, Villejuif, 94800, France.,Department of Surgery, Gustave Roussy Cancer Center, Villejuif, 94800, France.,Department of Dermatology, Gustave Roussy Cancer Center, Villejuif, 94800, France
| | - M J Smyth
- Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, 4006, Australia.,School of Medicine, University of Queensland, Herston, QLD, 4006, Australia
| | - J S Weber
- Laura & Isaac Perlmutter Cancer Center, New York University Medical Center, New York, NY, 10016, USA
| | - A M Eggermont
- Gustave Roussy Cancer Campus, Villejuif, 94800, France
| | - L Zitvogel
- INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France. .,University Paris-Saclay, Kremlin Bicêtre, 94 276, France. .,Gustave Roussy Cancer Campus, Villejuif, 94800, France. .,CIC1428, Gustave Roussy Cancer Campus, Villejuif, 94800, France. .,Gustave Roussy, Université Paris-Saclay, Service de Biostatistique et d'Epidémiologie, Villejuif, F-94805, France.
| |
Collapse
|
50
|
Fattouh K, Debarbieux S, Depaepe L, Amini-Adle M, Balme B, Thomas L. Routine use of perioperative in vivo
reflectance confocal microscopy of the nail matrix in melanonychia striata: a report of 30 cases. Br J Dermatol 2017; 177:570-573. [DOI: 10.1111/bjd.15106] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- K. Fattouh
- Department of Dermatology; Lyon 1 University, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud; 69495 Pierre Bénite CEDEX France
| | - S. Debarbieux
- Department of Dermatology; Lyon 1 University, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud; 69495 Pierre Bénite CEDEX France
| | - L. Depaepe
- Department of Pathology; Lyon 1 University, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud; 69495 Pierre Bénite CEDEX France
| | - M. Amini-Adle
- Department of Dermatology; Lyon 1 University, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud; 69495 Pierre Bénite CEDEX France
| | - B. Balme
- Department of Pathology; Lyon 1 University, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud; 69495 Pierre Bénite CEDEX France
| | - L. Thomas
- Department of Dermatology; Lyon 1 University, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud; 69495 Pierre Bénite CEDEX France
| |
Collapse
|